



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Design of the FP-RESTORE study: a prospective, observational study of real-world treatments with endovascular therapy in patients with femoropopliteal artery Tosaka III in-stent restenosis.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-060200
Article Type:	Protocol
Date Submitted by the Author:	15-Dec-2021
Complete List of Authors:	<p>Li, Xu; Zhongshan Hospital Fudan University, Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine</p> <p>Zhou, Min; Zhongshan Hospital Fudan University, Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine</p> <p>Ding, Yong; Zhongshan Hospital Fudan University, Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine</p> <p>Wu, Ziheng; Zhejiang University School of Medicine First Affiliated Hospital, Department of Vascular Surgery</p> <p>Feng, Zibo; Liyuan Hospital of Tongji Medical College of Huazhong University of Science and Technology, Department of Vascular Surgery</p> <p>guo, Lianrui; Xuanwu Hospital Capital Medical University, Department of Vascular Surgery</p> <p>Li, Qiang; Qingdao Haici Hospital, Department of Vascular Surgery</p> <p>Fang, Xin; Affiliated Hangzhou First People's Hospital Zhejiang University School of Medicine, Department of Vascular Surgery</p> <p>Sang, Hongfei; Second Affiliated Hospital of Soochow University, Department of Vascular Surgery</p> <p>Ye, Meng; Shanghai Jiaotong University, Department of Vascular Surgery</p> <p>Shi, Zhenyu; Zhongshan Hospital Fudan University, Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine</p>
Keywords:	Interventional radiology < RADIOLOGY & IMAGING, Vascular surgery < SURGERY, Clinical trials < THERAPEUTICS

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Design of the FP-RESTORE study: a prospective, observational study of real-world treatments with endovascular therapy in patients with femoropopliteal artery Tosaka III in-stent restenosis.**

**AUTHORS :**

**Xu Li, XL**, MD, Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine, Shanghai, China. **E-mail:** [lixu007qq@163.com](mailto:lixu007qq@163.com)

**Min Zhou, MZ**, MD, PhD, Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine, Shanghai, China. E-mail: [med-zhou@foxmail.com](mailto:med-zhou@foxmail.com)

**Yong Ding, YD**, MD, PhD Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine, Shanghai, China. E-mail: [Med.YoungDee@gmail.com](mailto:Med.YoungDee@gmail.com)

**Ziheng Wu, ZW**, MD, PhD Department of Vascular Surgery, the First Affiliated hospital of Medicine College of Zhejiang University, Hangzhou, China. E-mail: [wuziheng@zju.edu.cn](mailto:wuziheng@zju.edu.cn).

**Zibo Feng, ZF**, MD, PhD, Department of Vascular Surgery, Liyuan Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan, China E-mail: [390306820@qq.com](mailto:390306820@qq.com)

**Lianrui Guo, LG**, MD, PhD, Department of Vascular Surgery, Xuanwu Hospital

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Capital Medical University, Beijing, China E-mail: [lianruiguo@sina.com](mailto:lianruiguo@sina.com)

2 **Qiang Li, QL**, MD, PhD, Department of Vascular Surgery, Qingdao Haici hospital

3 affiliated to Qingdao University, Qingdao, China E-mail: [haicixueguan@163.com](mailto:haicixueguan@163.com)

4 **Xin Fang, XF**, MD, PhD, Department of Vascular Surgery, Hangzhou First People's

5 hospital of Medical College of Zhejiang University, Hangzhou, China. E-

6 mail:[hzhfx@126.com](mailto:hzhfx@126.com)

7 **Hongfei Sang, HS**, MD, PhD Department of Vascular Surgery, the second Affiliated

8 Hospital of Medical College of Suzhou University, Suzhou, China.

9 [sanghf@yahoo.com.cn](mailto:sanghf@yahoo.com.cn)

10 **Meng Ye\*, MY**, Department of Vascular Surgery, Renji Hospital, School of

11 Medicine, Shanghai Jiaotong University, Shanghai, China. Email:

12 [doctor\\_yemeng2018@163.com](mailto:doctor_yemeng2018@163.com)

13 **Zhenyu Shi\*, ZS**, MD, PhD, Department of Vascular Surgery, Zhongshan Hospital,

14 Institute of Vascular Surgery, Fudan University, National Clinical Research Center

15 for Interventional Medicine, Shanghai, China. E-mail: [shizhenyumax@163.com](mailto:shizhenyumax@163.com)

16

17 Xu Li\* and Min Zhou\* contribute to this work equally.

18 **Word count, total:** 2160

19 **Word count, abstract:** 242

20 **CORRESPONDING AUTHOR:**

21 Meng Ye, Department of Vascular Surgery, Renji Hospital, School of Medicine,

22 Shanghai Jiaotong University

1 Pujian Road 160, Shanghai 200127, China.  
2  
3  
4  
5  
6 Email: doctor\_yemeng2018@163.com  
7  
8  
9 Zhenyu Shi, Department of Vascular Surgery, Zhongshan Hospital, Institute of  
10  
11  
12 Vascular Surgery, Fudan University, National Clinical Research Center for  
13  
14  
15 Interventional Medicine, Shanghai, China.  
16  
17 180 Fenglin Road, 200032, Shanghai, China  
18  
19  
20 Tel.: 8621-6404-1990 ext. 2359  
21  
22  
23 Fax: 8621-6443-2410  
24  
25 E-mail address: shizhenyumax@163.com  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Abstract**

**Introduction:** Femoropopliteal artery in-stent restenosis(FP-ISR) has become one of the main blocks for stent implantation in PAD patients, especially Tosaka III FP-ISR, which is also called in-stent occlusion. The endovascular treatments of Tosaka III FP-ISR are diverse and the effects are also remained controversial and real-world data are scarce. This study aims to evaluate the efficacy, safety and health economics evaluation of various endovascular procedures in treating Tosaka III FP-ISR.

**Method and analysis**

This study is a prospective, multicenter, real-world, observational clinical study. Patients diagnosed with Tosaka III FP-ISR and treated with endovascular procedures in 9 centers from 1 April 2021 to 31 December 2022 will be recruited. The relevant clinical information, ankle-brachial index and CT angiography will be collected. All the participants will undergo follow-up at 1, 6, 12,18 and 24 months after operation. The primary outcome is freedom from target lesion revascularization at 24-month. The safety and health economics issues are also planned to be reported.

**Ethics and dissemination**

The FP-RESTORE clinical trial has been registered in ClinicalTrial (<http://clinicaltrials.gov/>). This study has also been approved by the Institutional review board and Human Research Ethics Committee of Zhongshan hospital, Fudan university(Approved number: B2021-427). Moreover, the written informed consent will be obtained at the time of recruitment. The study outcomes will be disseminated by publication in a peer-reviewed journal to provide information for further clinical

practice.

**Trial registration number** : Number: NCT04801004.

**Protocol version and date** : V.1.1, 1 April 2021.

## **Strengths and limitation of this study**

1. This study is a prospective, multicenter, real-world, observational clinical study.

2. This study majors in the efficacy, safety and health economics evaluation of

various endovascular operations in treating Tosaka III FP-ISR.

3. This is an observational study and no interference with endovascular treatments

will take place.

4. The Tosaka III FP-ISR patients usually have poor prognosis and may withdraw due to adverse events in early stage.

## **Introduction:**

Femoropopliteal artery is one of most common treated peripheral artery diseases (PAD).<sup>1</sup> The treatment modalities cover mainly conservative treatment, endovascular procedures and surgical operations, with endovascular treatment more widely applied. However, femoropopliteal artery in-stent restenosis(FP-ISR) has become one of the main blocks for stent implantation in PAD patients with high morbidity, especially Tosaka III in-stent restenosis which is also named in-stent obstruction.<sup>2,3</sup> Tosaka et al reported the freedom from recurrent ISR at 12-month is 22.7% of TOSAKA III



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 lesions compared with 72.5% and 65.6% in Tosaka I and II lesions, respectively.<sup>4</sup>

2 Meanwhile, Armstrong et al reported the freedom from recurrent restenosis at 24-

3 month was 28% of Tosaka III lesions compared with 61% and 34% in TOSAKA I

4 and II lesions, respectively.<sup>5</sup> This indicated in-stent occlusion correlated with worse

5 prognosis compared with in-stent restenosis.

6 The endovascular procedures employed to treat FP-ISR include balloon

7 angioplasty(BA) alone, drug-coated balloon(DCB), cutting balloon, bare metal

8 stent(BMS), covered stent, mechanical debulking devices, laser atherectomy(LA) or

9 the combination of above.<sup>6-13</sup> Giannopoulos et al reported freedom from TLR in 12-

10 month estimate to 88.9% in LA + DCB group compared with 54.2% in LA + BA

11 group in treating Tosaka III FP-ISR.<sup>14</sup> Meanwhile, Zhang et al reported the results of

12 DCB treating Tosaka III FP-ISR: primary patency and freedom from TLR estimate to

13 79.2% and 91.5% at 14-month follow-up.<sup>15</sup> Debulking devices(laser debulking or

14 mechanical debulking devices) have also been widely used in treating FP-ISR. Our

15 previously study has also demonstrated that the patients with long and occlusive ISR

16 lesion benefit more from debulking devices compared with short and stenosis ISR

17 lesions.<sup>16</sup> Previous studies have reported roles for mechanical atherothrombectomy in

18 treating femoropopliteal artery Tosaka III in-stent restenosis, the freedom from TLR

19 at 12-month ranged from 80.5% to 94.5%.<sup>17</sup> The outcomes for endovascular treated

20 Tosaka III FP-ISR are varied. Thus, there is need for a real-world setting outcome to

21 distinguish and evaluate the safety, efficacy and economic cost of different

22 endovascular modalities in treating Tosaka III FP-ISR. In real-world setting, the trial

could recruit the patients with in-stent occlusion rather than mild in-stent restenosis lesions.

Although there have been clinical reports about the preliminary and midterm stage results of different endovascular treatments in treating Tosaka III FP-ISR patients, these results were still insufficient to reflect the real-world clinical practice. Thus, we initiated a clinical trial named FP-RESTORE study to examine the safety, effectiveness and economic cost of different endovascular therapies in treating Tosaka III FP-ISR patients in a real-world setting across China.

## **METHODS**

### **Study design**

FP-RESTORE is a prospective, multicenter, real-world, observational clinical study, which aims at evaluating the safety, efficacy and economic cost of different endovascular therapies in Tosaka III (totally occluded) in-stent restenosis. It is estimated that 300 subjects diagnosed with femoropopliteal artery Tosaka III in-stent restenosis and receiving endovascular treatments is being enrolled in nine centers from April 2021 to December 2022 nationwide in China. There was no restriction of the endovascular techniques used to make it easier to compare effects of different endovascular treatments in Tosaka III in-stent restenosis.

The main purpose is to observe the freedom from TLR(target lesion revascularization), primary patency, the improvement of quality-of-life score, and Health economics evaluation.

The study is designed and initiated by the Department of Vascular Surgery,

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Zhongshan Hospital, Fudan University. Patient and public involvement No patient or  
2 public involvement.

3 **Participants**

4 To minimize bias in the selection of patients, investigators at participating sites  
5 are encouraged to enroll all eligible Tosaka III in-stent restenosis patients receiving  
6 endovascular treatments. The patients are being screened for enrollment from April  
7 2021 to December 2022 in nine designated centers across China. A total number of  
8 300 patients who had received stent implantation to treat PAD and developed Tosaka  
9 III FP-ISR will be recruited. Recruitment is non-competitive and will not affect  
10 clinical practice.

11 **CRITERIA**

12 **Inclusion criteria**

- 13 1.Tosaka III In-stent restenosis after stent implantation in PAD patients. (Including  
14 acute and subacute thrombotic lesions).  
15 2.The length of occluded lesion is  $\geq 5$ cm.  
16 3. Rutherford grade 2-5, symptoms of claudication or resting pain or localized  
17 gangrenous ulcer.  
18 4. Stents should be located in the femoralpopliteal artery.  
19 5.The stenosis of iliac artery on the affected side is less than 30% or the residual  
20 stenosis after treatment is less than 30%.  
21 6.Informed consent has been signed

22 **Exclusion criteria**

1. Tosaka I or II in-stent restenosis or stent occlusion lesion less than 5cm in length.
2. Stents are located in iliac artery, or artery below the knee, or the preoperative CTA showed type 3 or 4 stent fracture.
3. Rutherford Grade 6.
4. Thromboangiitis obliterans (TAO) based, arteritis-based or connective tissue disorder-based FP-ISR.
5. Intraoperative conversion to hybrid or open surgery.
6. Patients refusing to sign informed consent.
7. Life expectancy of patients is less than 12 months.
8. The pregnant or nursing patients.
9. The patients with severe ischemia of lower extremity who would receive major amputation in plan.
10. Patients in whom antiplatelet or anticoagulant therapy is contraindicated.
11. Myocardial infarction or stroke within 3 months prior to enrollment.
12. Patient with known allergy to contrast agents or medications used to perform endovascular intervention.
13. Patients participating in another research study involving an investigational agent (pharmaceutical, biologic, or medical device) that has not reached the primary endpoint.
14. Patients who refuse to cooperate with long-term follow-up , or who have difficulty communicating.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Criteria for discontinuing**

Subjects could discontinue participation in this trial at any time for any reason without any consequences. Besides, the investigators could decide whether to discontinue the patient or not depending on the following condition.

- 1. The patients are lost to follow-up.
- 2. The patients voluntarily withdraw their informed consent.
- 3. In case of serious violation of the study protocol by investigators or subjects.
- 4. The subject is necessary to discontinue form the study for other reasons.

Once the subject discontinues participation in the trial, his/her relevant primary outcomes and secondary outcomes would be eliminated.

**Endovascular procedure**

All enrolled patient will be treated with endovascular therapies. In general, endovascular approaches are established from the contralateral common femoral artery or the ipsilateral common femoral artery or a brachial approach. A retrograde puncture access via popliteal artery will be chosen once intervention with the antegrade approach is unsuccessful. Followed by angiography to assess the lesion severity, length and location, the guide wire will be passed through the in-stent occlusion lesion. Then multiple types of endovascular treatments will be applied according to the characteristics of the lesion and physician preferences. For instance: BA, DCB, DES implantation, BMS implantation, intravascular lithotripsy, directional atherectomy, laser debulking , stent-grafts implantation or combination of above.

Final angiography is performed to assess the efficacy of endovascular treatment. The residual stenosis of less than 30% will be defined as technical success.

## **Recruitment**

All suitable patients will receive a routine examination during admission. Patients will receive intraoperative angiography of lower extremity artery, the lesion length, stenosis degree, extent of lesion, collateral circulation will be assessed. Moreover, eligible patients will be enrolled after signing the informed consent.

## **Data collection**

A standard case report form (CRF) has been established at the beginning of this study. This CRF will collect the patients' quality of life (QoL), systemic diseases history, perioperative risk factors assessment, clinical symptom classification, the location of lesion and Trans-Atlantic Inter-Society Consensus II (TASC) classification, endovascular procedure details, the treatment outcomes and complications as well as follow-up information. Two investigators perform the data input independently and the data input verification is conducted to lower the chance of error. The original CRF will be archived by sponsor, the copy of CRF is kept at center and transferred into electronic records in correlated data management system. This system covers preoperative assessment, intraoperative detail and follow-up information.

## **Surveillance and follow-up**

Follow-up will be coordinated by each participating centers independently. The

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 follow-up information come from via telephone interviews and outpatients clinical  
2 visits. The telephone interview follow-up information covers ambulation  
3 improvements, current medication, smoking status, wound healing(if necessary),  
4 rehospitalization and quality of life. Outpatients clinical visits follow- up information  
5 covers ABI, Rutherford classification, vascular ultrasound, the need of reintervention  
6 and presence of new-onset lesions.

7 These relevant details will also be recorded in CRF and transferred into electronic  
8 records in the lower extremity artery data management system. All centers  
9 participating in this study have access to the data. The participant’s personal  
10 information will be kept encrypted to prevent leakage. All the participants will  
11 undergo follow-up at 1, 6, 12,18 and 24 months after operation.

12 **Outcome measures**

13 The primary outcome of the study is freedom from TLR at 24-month. TLR is defined  
14 as any reintervention performed for more than 50% diameter stenosis at target  
15 lesion.<sup>18</sup> Freedom form TLR were defined as the rates of the number of patients who  
16 did not receive reintervention verse the number of patients during the follow-up  
17 period. The secondary outcomes cover 1)Primary patency, which defined as the  
18 percentage of stent patency examined by DUS or CTA examination during follow-up.  
19 2)Technical success rate. 3)incidence of major adverse events. 4)freedom from TLR  
20 at 1, 6, 12 and 18 months. 5) Vascular quality of life questionnaire(VascuQol), which  
21 contains five domains: pain (4 items), symptoms (4 items), activities (8 items), social  
22 (2 items), and emotional (7 items) to evaluate Health related quality of life (HRQL).

6) health economics evaluation, which defined as all the cost related to the target vessel revascularization in the inpatient ward.

### **Adverse events**

The adverse events will be categorized into minor and major adverse events and the frequency of minor and major adverse events during the treatment period and follow-up period will both be recorded. The minor adverse events cover arterial puncture complications, distal embolism without clinical manifestations, postoperative thrombosis without critical limb ischemia, reversible contrast induced nephropathy. Meanwhile, major adverse events cover major amputation related to endovascular treatment, cardio and cerebrovascular events arterial puncture complications requiring intervention, progressive decrease of hemoglobin, acute renal failure and death. Once adverse events are identified, the corresponding centers will deal with it positively. The adverse events and the process of treatment will be documented and report to the corresponding ethics committee. Once death events occur, the corresponding centers and the participating investigator should provide all necessary information to ethics committee immediately.

### **Sample size and statistical analysis**

Taking into account a lost follow-up rate of 10% and a target enrollment of 300 patients, 270 patients will be accessible for effectiveness analysis.

Statistical analysis will be performed using Stata SE 15.1 software (Stata Corp, College Station, TX, USA). Continuous data are presented as the mean  $\pm$  standard



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

deviation, and categorical data are presented as numbers (n) and percentages (%).

Normal distribution and homogeneous tests of variance will be performed in advance. For the data groups that have a normal distribution and homogeneous variances, comparisons between two groups will be made using unpaired Student's t-tests, and one-way ANOVA followed by Bonferroni tests for multiple groups comparisons. For the data groups that do not have a normal distribution or homogeneous variances, nonparametric tests will be used. Univariate and multivariate analyses will be performed by logistic analysis. Generally, a *P* value < 0.05 at the bilateral will be considered statistically significant unless otherwise stated.

**Ethics and dissemination**

The study protocol has been approved by the Institutional review board and Human Research Ethics Committee of Zhongshan hospital, Fudan university(B2021-427). All the patients will be informed their voluntary participation and given their written informed consent. The trial protocol complies with Declaration of Helsinki.

The medical record information and all the data are kept confidential and stored in secure data bases. The personal information of participants will be coded and password-protected.

The study outcomes will be disseminated by publication in a peer-reviewed journal. The relevant confidential information will be transferred into specific code to avoid potential leakage. Besides, trial design has also been registered at Clinical trials.gov(Number: NCT04801004).

**Author Contributors:** Authors have been included in this manuscript based on the ICMJE recommendations. XL, MZ, YD, and ZS planned and designed the study. MY and ZW reviewed the structure of this manuscript. XL, MY, ZW ZF, LG, QL, XF and HS contributed to patient enrollment and collection of patient data. ZS critically reviewed and approved this manuscript. All authors have read and approved the final manuscript.

**Funding:** This work was supported by the National Natural Science Foundation of China (Grant number : 81870342 from ZS)

**Acknowledgements:** None

**Competing interests :** None

**Patient informed consent :** Obtained

**Ethics approval :** The study protocol has been approved by the Institutional review board and Human Research Ethics Committee of Zhongshan hospital, Fudan university(B2021-427).

**Provenance and peer review:** Not commissioned; externally peer reviewed.

**Data sharing:** No additional data are available.

## Reference

1. Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. *Lancet* 2013;382(9901):1329-40.
2. Ho KJ, Owens CD. Diagnosis, classification, and treatment of femoropopliteal artery in-stent restenosis. *J Vasc Surg* 2017;65(2):545-57.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 3. Shammas NW, Jones-Miller S, Lemke J. Meta-Analysis-Derived Benchmarks of  
2 Patency and Target Lesion Revascularization of Percutaneous Balloon Angioplasty  
3 from Prospective Clinical Trials of Symptomatic Femoropopliteal In-Stent  
4 Restenosis. *J Vasc Interv Radiol* 2016;27(8):1195-203.

5 4. Tosaka A, Soga Y, Iida O, et al. Classification and clinical impact of restenosis  
6 after femoropopliteal stenting. *J Am Coll Cardiol* 2012;59(1):16-23.

7 5. Armstrong EJ, Singh S, Singh GD, et al. Angiographic characteristics of  
8 femoropopliteal in-stent restenosis: association with long-term outcomes after  
9 endovascular intervention. *Catheter Cardiovasc Interv* 2013;82(7):1168-74.

10 6. Beschorner U, Zeller T. Combination of mechanical atherectomy and drug-eluting  
11 balloons for femoropopliteal in-stent restenosis. *J Cardiovasc Surg (Torino)*  
12 2014;55(3):347-9.

13 7. Zeller T, Dake MD, Tepe G, et al. Treatment of femoropopliteal in-stent restenosis  
14 with paclitaxel-eluting stents. *JACC Cardiovasc Interv* 2013;6(3):274-81.

15 8. Shammas NW, Shammas GA, Hafez A, et al. Safety and One-Year  
16 revascularization outcome of excimer laser ablation therapy in treating in-stent  
17 restenosis of femoropopliteal arteries: A retrospective review from a single center.  
18 *Cardiovasc Revasc Med* 2012;13(6):341-4.

19 9. Murata N, Takahara M, Soga Y, et al. Drug-Eluting Stent vs Percutaneous  
20 Transluminal Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis:  
21 Results From a Retrospective 1-Year Multicenter Study. *J Endovasc Ther*  
22 2016;23(4):642-7.

10. Shamma NW, Shamma GA, Helou TJ, et al. Safety and 1-year revascularization outcome of SilverHawk atherectomy in treating in-stent restenosis of femoropopliteal arteries: a retrospective review from a single center. *Cardiovasc Revasc Med* 2012;13(4):224-7.
11. Laird JR, Jr., Yeo KK, Rocha-Singh K, et al. Excimer laser with adjunctive balloon angioplasty and heparin-coated self-expanding stent grafts for the treatment of femoropopliteal artery in-stent restenosis: twelve-month results from the SALVAGE study. *Catheter Cardiovasc Interv* 2012;80(5):852-9.
12. Dick P, Sabeti S, Mlekusch W, et al. Conventional balloon angioplasty versus peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent restenosis: initial experience. *Radiology* 2008;248(1):297-302.
13. Shamma NW, Shamma GA, Banerjee S, et al. JetStream Rotational and Aspiration Atherectomy in Treating In-Stent Restenosis of the Femoropopliteal Arteries: Results of the JETSTREAM-ISR Feasibility Study. *J Endovasc Ther* 2016;23(2):339-46.
14. Giannopoulos S, Kokkinidis DG, Jawaaid O, et al. Turbo-Power Laser Atherectomy Combined with Drug-coated Balloon Angioplasty is Associated with Improved One-Year Outcomes for the Treatment of Tosaka II and III Femoropopliteal In-stent Restenosis. *Cardiovasc Revasc Med* 2020;21(6):771-78.
15. Zhang B, Niu G, Yan Z, et al. Drug-Coated Balloon for the Treatment of Femoropopliteal Tosaka Class III In-stent Restenosis Lesions. *Front Surg* 2020;7:616414.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

16. Li X, Zhou M, Ding Y, et al. A systematic review and meta-analysis of the efficacy of debulking devices for in-stent restenosis of the femoropopliteal artery. *J Vasc Surg* 2020;72(1):356-66 e5.

17. Milnerowicz A, Milnerowicz A, Kuliczkowski W, et al. Rotational Atherectomy Plus Drug-Coated Balloon Angioplasty for the Treatment of Total In-Stent Occlusions in Iliac and Infrainguinal Arteries. *J Endovasc Ther* 2019;26(3):316-21.

18. Dippel EJ, Makam P, Kovach R, et al. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCimer Laser Randomized Controlled Study for Treatment of Femoropopliteal In-Stent Restenosis). *JACC Cardiovasc Interv* 2015;8(1 Pt A):92-101.

# Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. BMJ. 2013;346:e7586

Reporting Item			Page Number
<b>Administrative information</b>			
Title	<a href="#">#1</a>	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	<a href="#">#2a</a>	Trial identifier and registry name. If not yet registered, name of intended registry	4
Trial registration: data set	<a href="#">#2b</a>	All items from the World Health Organization Trial Registration Data Set	5
Protocol version	<a href="#">#3</a>	Date and version identifier	5
Funding	<a href="#">#4</a>	Sources and types of financial, material, and other support	15
Roles and responsibilities: contributorship	<a href="#">#5a</a>	Names, affiliations, and roles of protocol contributors	1-2

1	Roles and	<a href="#">#5b</a>	Name and contact information for the trial sponsor	n/a
2	responsibilities:			
3	sponsor contact			
4	information			
5				
6				
7				
8	Roles and	<a href="#">#5c</a>	Role of study sponsor and funders, if any, in study design;	n/a
9	responsibilities:		collection, management, analysis, and interpretation of data;	
10	sponsor and funder		writing of the report; and the decision to submit the report for	
11			publication, including whether they will have ultimate authority	
12			over any of these activities	
13				
14				
15				
16	Roles and	<a href="#">#5d</a>	Composition, roles, and responsibilities of the coordinating centre,	15
17	responsibilities:		steering committee, endpoint adjudication committee, data	
18	committees		management team, and other individuals or groups overseeing the	
19			trial, if applicable (see Item 21a for data monitoring committee)	
20				
21				
22				
23	<b>Introduction</b>			
24				
25	Background and	<a href="#">#6a</a>	Description of research question and justification for undertaking	5-7
26	rationale		the trial, including summary of relevant studies (published and	
27			unpublished) examining benefits and harms for each intervention	
28				
29				
30				
31	Background and	<a href="#">#6b</a>	Explanation for choice of comparators	7
32	rationale: choice of			
33	comparators			
34				
35				
36	Objectives	<a href="#">#7</a>	Specific objectives or hypotheses	6
37				
38	Trial design	<a href="#">#8</a>	Description of trial design including type of trial (eg, parallel	7
39			group, crossover, factorial, single group), allocation ratio, and	
40			framework (eg, superiority, equivalence, non-inferiority,	
41			exploratory)	
42				
43				
44				
45	<b>Methods:</b>			
46	<b>Participants,</b>			
47	<b>interventions, and</b>			
48	<b>outcomes</b>			
49				
50				
51				
52	Study setting	<a href="#">#9</a>	Description of study settings (eg, community clinic, academic	7
53			hospital) and list of countries where data will be collected.	
54			Reference to where list of study sites can be obtained	
55				
56				
57	Eligibility criteria	<a href="#">#10</a>	Inclusion and exclusion criteria for participants. If applicable,	8-9
58			eligibility criteria for study centres and individuals who will	
59				
60				

		perform the interventions (eg, surgeons, psychotherapists)	
Interventions: description	<a href="#">#11a</a>	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	10
Interventions: modifications	<a href="#">#11b</a>	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	9-10
Interventions: adherence	<a href="#">#11c</a>	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	11
Interventions: concomitant care	<a href="#">#11d</a>	Relevant concomitant care and interventions that are permitted or prohibited during the trial	11-12
Outcomes	<a href="#">#12</a>	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	12
Participant timeline	<a href="#">#13</a>	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	12
Sample size	<a href="#">#14</a>	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	13
Recruitment	<a href="#">#15</a>	Strategies for achieving adequate participant enrolment to reach target sample size	11
<b>Methods: Assignment of interventions (for controlled trials)</b>			
Allocation: sequence generation	<a href="#">#16a</a>	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	n/a



1	Allocation concealment	<a href="#">#16b</a>	Mechanism of implementing the allocation sequence (eg, central	n/a
2	mechanism		telephone; sequentially numbered, opaque, sealed envelopes),	
3			describing any steps to conceal the sequence until interventions are	
4			assigned	
5				
6				
7				
8	Allocation:	<a href="#">#16c</a>	Who will generate the allocation sequence, who will enrol	n/a
9	implementation		participants, and who will assign participants to interventions	
10				
11	Blinding (masking)	<a href="#">#17a</a>	Who will be blinded after assignment to interventions (eg, trial	n/a
12			participants, care providers, outcome assessors, data analysts), and	
13			how	
14				
15				
16				
17	Blinding (masking):	<a href="#">#17b</a>	If blinded, circumstances under which unblinding is permissible,	n/a
18	emergency unblinding		and procedure for revealing a participant's allocated intervention	
19			during the trial	
20				
21				
22	<b>Methods: Data</b>			
23	<b>collection,</b>			
24	<b>management, and</b>			
25	<b>analysis</b>			
26				
27				
28				
29	Data collection plan	<a href="#">#18a</a>	Plans for assessment and collection of outcome, baseline, and other	11
30			trial data, including any related processes to promote data quality	
31			(eg, duplicate measurements, training of assessors) and a	
32			description of study instruments (eg, questionnaires, laboratory	
33			tests) along with their reliability and validity, if known. Reference	
34			to where data collection forms can be found, if not in the protocol	
35				
36				
37				
38				
39	Data collection plan:	<a href="#">#18b</a>	Plans to promote participant retention and complete follow-up,	11
40	retention		including list of any outcome data to be collected for participants	
41			who discontinue or deviate from intervention protocols	
42				
43				
44	Data management	<a href="#">#19</a>	Plans for data entry, coding, security, and storage, including any	11
45			related processes to promote data quality (eg, double data entry;	
46			range checks for data values). Reference to where details of data	
47			management procedures can be found, if not in the protocol	
48				
49				
50				
51	Statistics: outcomes	<a href="#">#20a</a>	Statistical methods for analysing primary and secondary outcomes.	13
52			Reference to where other details of the statistical analysis plan can	
53			be found, if not in the protocol	
54				
55				
56	Statistics: additional	<a href="#">#20b</a>	Methods for any additional analyses (eg, subgroup and adjusted	14
57	analyses		analyses)	
58				
59				
60				

Statistics: analysis population and missing data	<a href="#">#20c</a>	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	14
<b>Methods: Monitoring</b>			
Data monitoring: formal committee	<a href="#">#21a</a>	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	n/a
Data monitoring: interim analysis	<a href="#">#21b</a>	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	n/a
Harms	<a href="#">#22</a>	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	n/a
Auditing	<a href="#">#23</a>	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	n/a
<b>Ethics and dissemination</b>			
Research ethics approval	<a href="#">#24</a>	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	15
Protocol amendments	<a href="#">#25</a>	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	15
Consent or assent	<a href="#">#26a</a>	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	15
Consent or assent: ancillary studies	<a href="#">#26b</a>	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	15
Confidentiality	<a href="#">#27</a>	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	11

1	Declaration of interests	<a href="#">#28</a>	Financial and other competing interests for principal investigators for the overall trial and each study site	15
2				
3				
4				
5	Data access	<a href="#">#29</a>	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	11
6				
7				
8				
9				
10	Ancillary and post trial care	<a href="#">#30</a>	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a
11				
12				
13				
14	Dissemination policy: trial results	<a href="#">#31a</a>	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	15
15				
16				
17				
18				
19				
20				
21	Dissemination policy: authorship	<a href="#">#31b</a>	Authorship eligibility guidelines and any intended use of professional writers	15
22				
23				
24				
25	Dissemination policy: reproducible research	<a href="#">#31c</a>	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	15
26				
27				
28				
29	<b>Appendices</b>			
30				
31	Informed consent materials	<a href="#">#32</a>	Model consent form and other related documentation given to participants and authorised surrogates	n/a
32				
33				
34				
35	Biological specimens	<a href="#">#33</a>	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a
36				
37				
38				
39				

40 The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative Commons  
41 Attribution License CC-BY-NC. This checklist was completed on 10. December 2021 using  
42 <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59

# BMJ Open

## Design of the FP-RESTORE study: A protocol for prospective, observational study of real-world treatments with endovascular therapy in patients with femoropopliteal artery Tosaka III in-stent restenosis.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-060200.R1
Article Type:	Protocol
Date Submitted by the Author:	27-Apr-2022
Complete List of Authors:	<p>Li, Xu; Zhongshan Hospital Fudan University, Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine</p> <p>Zhou, Min; Zhongshan Hospital Fudan University, Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine</p> <p>Ding, Yong; Zhongshan Hospital Fudan University, Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine</p> <p>Wu, Ziheng; Zhejiang University School of Medicine First Affiliated Hospital, Department of Vascular Surgery</p> <p>Feng, Zibo; Liyuan Hospital of Tongji Medical College of Huazhong University of Science and Technology, Department of Vascular Surgery</p> <p>guo, Lianrui; Xuanwu Hospital Capital Medical University, Department of Vascular Surgery</p> <p>Li, Qiang; Qingdao Haici Hospital, Department of Vascular Surgery</p> <p>Fang, Xin; Affiliated Hangzhou First People's Hospital Zhejiang University School of Medicine, Department of Vascular Surgery</p> <p>Sang, Hongfei; Second Affiliated Hospital of Soochow University, Department of Vascular Surgery</p> <p>Ye, Meng; Shanghai Jiaotong University, Department of Vascular Surgery</p> <p>Shi, Zhenyu; Zhongshan Hospital Fudan University, Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine</p>
<b>Primary Subject Heading</b>:	Surgery
Secondary Subject Heading:	Surgery
Keywords:	Interventional radiology < RADIOLOGY & IMAGING, Vascular surgery < SURGERY, Clinical trials < THERAPEUTICS



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Design of the FP-RESTORE study: A protocol for prospective, observational study of real-world treatments with endovascular therapy in patients with femoropopliteal artery Tosaka III in-stent restenosis.**

**AUTHORS :**

**Xu Li, XL**, MD, Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine, Shanghai, China. **E-mail:** [lixu007qq@163.com](mailto:lixu007qq@163.com)

**Min Zhou, MZ**, MD, PhD, Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine, Shanghai, China. E-mail: [med-zhou@foxmail.com](mailto:med-zhou@foxmail.com)

**Yong Ding, YD**, MD, PhD Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine, Shanghai, China. E-mail: [Med.YoungDee@gmail.com](mailto:Med.YoungDee@gmail.com)

**Ziheng Wu, ZW**, MD, PhD Department of Vascular Surgery, the First Affiliated hospital of Medicine College of Zhejiang University, Hangzhou, China. E-mail: [wuziheng@zju.edu.cn](mailto:wuziheng@zju.edu.cn).

**Zibo Feng, ZF**, MD, PhD, Department of Vascular Surgery, Liyuan Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan, China E-mail: [390306820@qq.com](mailto:390306820@qq.com)

**Lianrui Guo, LG**, MD, PhD, Department of Vascular Surgery, Xuanwu Hospital

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Capital Medical University, Beijing, China E-mail: [lianruiguo@sina.com](mailto:lianruiguo@sina.com)

2 **Qiang Li, QL**, MD, PhD, Department of Vascular Surgery, Qingdao Haici hospital

3 affiliated to Qingdao University, Qingdao, China E-mail: [haicixueguan@163.com](mailto:haicixueguan@163.com)

4 **Xin Fang, XF**, MD, PhD, Department of Vascular Surgery, Hangzhou First People's

5 hospital of Medical College of Zhejiang University, Hangzhou, China. E-

6 mail:[hzhfx@126.com](mailto:hzhfx@126.com)

7 **Hongfei Sang, HS**, MD, PhD Department of Vascular Surgery, the second Affiliated

8 Hospital of Medical College of Suzhou University, Suzhou, China.

9 [sanghf@yahoo.com.cn](mailto:sanghf@yahoo.com.cn)

10 **Meng Ye\*, MY**, MD, PhD Department of Vascular Surgery, Renji Hospital, School

11 of Medicine, Shanghai Jiaotong University, Shanghai, China. Email:

12 [doctor\\_yemeng2018@163.com](mailto:doctor_yemeng2018@163.com)

13 **Zhenyu Shi\*, ZS**, MD, PhD, Department of Vascular Surgery, Zhongshan Hospital,

14 Institute of Vascular Surgery, Fudan University, National Clinical Research Center

15 for Interventional Medicine, Shanghai, China. E-mail: [shizhenyumax@163.com](mailto:shizhenyumax@163.com)

16

17 Xu Li\* and Min Zhou\* contribute to this work equally.

18 **Word count, total:** 2393

19 **Word count, abstract:**243

20 **CORRESPONDING AUTHOR:**

21 Meng Ye, Department of Vascular Surgery, Renji Hospital, School of Medicine,

22 Shanghai Jiaotong University

1 Pujian Road 160, Shanghai 200127, China.  
2  
3  
4  
5  
6 Email: doctor\_yemeng2018@163.com  
7  
8  
9 Zhenyu Shi, Department of Vascular Surgery, Zhongshan Hospital, Institute of  
10  
11  
12 Vascular Surgery, Fudan University, National Clinical Research Center for  
13  
14  
15 Interventional Medicine, Shanghai, China.  
16  
17 180 Fenglin Road, 200032, Shanghai, China  
18  
19  
20 Tel.: 8621-6404-1990 ext. 2359  
21  
22  
23 Fax: 8621-6443-2410  
24  
25 E-mail address: shizhenyumax@163.com  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Abstract**

**Introduction:** Femoropopliteal artery in-stent restenosis (FP-ISR) represents one of the main obstacles for stent implantation in PAD patients, especially Tosaka III FP-ISR, which is also referred to as in-stent occlusion. Diverse endovascular treatments of Tosaka III FP-ISR are available, and the results are unequivocal. However, real-world data are limited. This study aims to evaluate the efficacy, safety and health economics evaluation of various endovascular procedures in the treatment of Tosaka III FP-ISR.

**Method and analysis**

This study is a prospective, multicentre, real-world, observational clinical study. Patients diagnosed with Tosaka III FP-ISR and treated with endovascular procedures in 9 centres from 1 April 2021 to 31 December 2022 will be recruited. The relevant clinical information, ankle-brachial index and CT angiography will be collected. All the participants will undergo follow-up at 1, 6, 12, 18 and 24 months after the operation. The primary outcome is freedom from clinically driven target lesion revascularization (CD-TLR) at 24 months. Safety and health economics issues will also be reported.

**Ethics and dissemination**

The FP-RESTORE clinical trial has been registered at ClinicalTrials.gov (<http://clinicaltrials.gov/>). This study was also approved by the Institutional Review Board and Human Research Ethics Committee of Zhongshan Hospital, Fudan University (approval number: B2021-427). Moreover, written informed consent will

be obtained at the time of recruitment. The study outcomes will be disseminated by publication in a peer-reviewed journal to provide information for further clinical practice.

**Trial registration number:** NCT04801004.

**Protocol version and date:** V.1.1, 1 April 2021.

### **Strengths and limitations of this study**

1. This study is a prospective, multicentre, real-world, observational clinical study.
2. This study focuses on the efficacy, safety and health economics evaluation of various endovascular operations in the treatment of Tosaka III FP-ISR.
3. This is an observational study, and no interference with endovascular treatments will occur.
4. The revascularization of Tosaka III FP-ISR usually have poor prognosis and may withdraw due to adverse events in early stage.

### **Introduction:**

The femoropopliteal artery is one of most commonly treated peripheral artery diseases (PAD).<sup>1</sup> The treatment modalities mainly include conservative treatment, endovascular procedures and surgical operations, with endovascular treatment being more widely applied. However, femoropopliteal artery in-stent restenosis (FP-ISR) has become one of the main blocks for stent implantation in PAD patients with high

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 morbidity, especially Tosaka III in-stent restenosis, which is also referred to as in-  
2 stent obstruction.<sup>2 3</sup> Tosaka et al. reported that the freedom from recurrent ISR at 12  
3 months was 22.7% for Tosaka III lesions compared with 72.5% and 65.6% for Tosaka  
4 I and II lesions, respectively.<sup>4</sup> Armstrong et al. reported that the freedom from  
5 recurrent restenosis at 24 months was 28% for Tosaka III lesions compared with 61%  
6 and 34% for TOSAKA I and II lesions, respectively.<sup>5</sup> This finding indicated that in-  
7 stent occlusion correlated with a worse prognosis than in-stent restenosis.

8       Giannopoulos et al. reported freedom from TLR of 88.9% in the laser debulking  
9 devices (LD) + drug coated balloons (DCB) group compared with 54.2% in the LD +  
10 balloon angioplasty (BA) group in a 12-month estimate for the treatment of Tosaka III  
11 FP-ISR.<sup>6</sup> Zhang et al. reported the results of DCB in the treatment of Tosaka III FP-  
12 ISR with primary patency and freedom from TLR estimates of 79.2% and 91.5%,  
13 respectively, at the 14-month follow-up.<sup>7</sup> Debulking devices (laser debulking or  
14 mechanical debulking devices) have also been widely used in the treatment of FP-  
15 ISR. Our previous meta-analysis demonstrated that patients with long and occlusive  
16 ISR lesions benefit more from debulking devices.<sup>8</sup> Previous studies have also reported  
17 roles for mechanical atherothrombectomy in the treatment of Tosaka III in-stent  
18 restenosis with freedom from TLR at 12 months ranging from 43.8% to 84.7%.<sup>9-12</sup>  
19 Given that the outcomes for endovascularly treated Tosaka III FP-ISR varied, there is  
20 a need for data from a real-world setting to evaluate the safety, efficacy and economic  
21 cost of different endovascular modalities in the treatment of Tosaka III FP-ISR. In a  
22 real-world setting, the trial could recruit patients with in-stent occlusion rather than

1 mild in-stent restenosis lesions.

2 Although there have been clinical reports about the preliminary and midterm  
3 stage results of different endovascular treatments in the treatment of Tosaka III FP-  
4 ISR patients, these results were still insufficient to reflect real-world clinical practice.  
5 Thus, we initiated a clinical trial named the FP-RESTORE study to examine the  
6 safety, effectiveness and economic cost of different endovascular therapies in the  
7 treatment of Tosaka III FP-ISR patients in a real-world setting across China.

## 8 **METHODS**

### 9 **Study design**

10 FP-RESTORE is a prospective, multicentre, real-world, observational clinical study  
11 that aims to evaluate the safety, efficacy and economic cost of different endovascular  
12 therapies in Tosaka III (totally occluded) in-stent restenosis. It is estimated that 300  
13 subjects diagnosed with femoropopliteal artery Tosaka III in-stent restenosis and  
14 receiving endovascular treatments will be enrolled in nine centres from April 2021 to  
15 December 2022 nationwide in China. No restrictions on the endovascular techniques  
16 used will be employed to make it easier to compare the effects of different  
17 endovascular treatments in Tosaka III in-stent restenosis.

18 The main purpose is to observe the freedom from clinically driven target lesion  
19 revascularization (CD-TLR), primary patency, the improvement in quality-of-life  
20 score, and health economics evaluation.

21 The study was designed and initiated by the Department of Vascular Surgery,  
22 Zhongshan Hospital, Fudan University. No patient or public involvement is required.

**Participants**

To minimize bias in the selection of patients, investigators at participating sites are encouraged to enroll all eligible Tosaka III in-stent restenosis patients receiving endovascular treatments. The patients will be screened for enrolment from April 2021 to December 2022 in nine designated centres across China. A total of 300 patients who received stent implantation to treat PAD and developed Tosaka III FP-ISR will be recruited. Recruitment is non-competitive and will not affect clinical practice.

**CRITERIA**

**Inclusion criteria**

1. Tosaka III In-stent restenosis after stent implantation in PAD patients (Including acute and subacute thrombotic lesions).
2. Rutherford grade 2-5.
3. Stents should be located in the femoropopliteal artery.
4. The stenosis of iliac artery on the affected side is less than 30% or the residual stenosis after treatment is less than 30%.
5. Informed consent has been signed

**Exclusion criteria**

1. Tosaka I or II in-stent restenosis.
2. Stents are located in iliac artery or artery below the knee, or the preoperative CTA showed type 3 or 4 stent fracture.
3. Rutherford Grade 6.
4. Thromboangiitis obliterans (TAO)-based, arteritis-based or connective tissue

1 disorder-based FP-ISR.

2 5. Intraoperative conversion to hybrid or open surgery.

3 6. Patients refusing to sign informed consent forms.

4 7. Life expectancy of patients is less than 12 months.

5 8. The pregnant or nursing patients.

6 9. The patients with severe ischemia of lower extremity who would receive major  
7 amputation in plan.

8 10. Patients in whom antiplatelet or anticoagulant therapy is contraindicated.

9 11. Myocardial infarction or stroke within 3 months prior to enrolment.

10 12. Patient with known allergy to contrast agents or medications used to perform  
11 endovascular intervention.

12 13. Patients participating in another research study involving an investigational agent  
13 (pharmaceutical, biologic, or medical device) that has not reached the primary  
14 endpoint.

15 14. Patients who refuse to cooperate with long-term follow-up or who have difficulty  
16 communicating.

17

## 18 **Criteria for discontinuing**

19 Subjects could discontinue participation in this trial at any time for any reason without  
20 any consequences. In addition, the investigators could decide whether the patient is  
21 excluded from the study depending on the following conditions.

22 1. The patients are lost to follow-up.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1     2. The patients voluntarily withdraw their informed consent.
- 2     3. In case of serious violation of the study protocol by investigators or subjects.
- 3     4. The subject must discontinue from the study for other reasons.
- 4     Once the subject discontinued participation in the trial, his or her relevant primary
- 5     outcomes and secondary outcomes would be eliminated.

7     **Endovascular procedure**

8             All enrolled patients will be treated with endovascular therapies. In general,

9     endovascular approaches are established from the contralateral common femoral

10    artery or the ipsilateral common femoral artery or a brachial approach. Retrograde

11    puncture access via the popliteal artery will be chosen once intervention with the

12    antegrade approach is unsuccessful. General angiography will be performed to assess

13    the lesion severity, length and location. Then, angiography of the target artery will be

14    performed, and the guide wire will be passed through the in-stent occlusion lesion.

15    Then, multiple types of endovascular treatments, including BA, DCB, drug eluting

16    stent (DES) implantation, bare metal stent (BMS) implantation, intravascular

17    lithotripsy, directional atherectomy, laser debulking, stent-graft implantation or a

18    combination of the above, will be applied according to the characteristics of the lesion

19    and physician preferences. Generally, BA and DCB will be used as the basis for

20    endovascular treatment of FR-ISR. Thrombectomy devices will be applied in acute or

21    subacute thrombosis lesions, and both laser debulking devices and atherectomy

22    debulking devices are preferred in chronic long lesions. The devices used

1 intraoperatively will be based on the operator's preferences. Final angiography will be  
2 performed to assess the efficacy of endovascular treatment. Residual stenosis of less  
3 than 30% will be defined as technical success.

## 4 5 **Recruitment**

6 All suitable patients will receive a routine examination during admission. Patients  
7 will receive intraoperative angiography of lower extremity artery, and data on the  
8 lesion length, stenosis degree, extent of lesion, collateral circulation will be assessed.  
9 Moreover, eligible patients will be enrolled after signing the informed consent form.

## 10 **Data collection**

11 A standard case report form (CRF) has been established at the beginning of this study.  
12 This CRF will collect the patients' quality of life (QoL), systemic disease history,  
13 perioperative risk factor assessment, clinical symptom classification, lesion location  
14 and Trans-Atlantic Inter-Society Consensus II (TASC) classification, endovascular  
15 procedure details, treatment outcomes and complications as well as follow-up  
16 information. Two investigators will perform the data input independently, and data  
17 input verification will be conducted to reduce the chance of error. The original CRF  
18 will be archived by the sponsor, and a copy of the CRF will be kept at the centre and  
19 transferred into electronic records in a correlated data management system. This  
20 system covers preoperative assessment, intraoperative details and follow-up  
21 information.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Surveillance and follow-up**

Follow-up will be coordinated by each participating centre independently. The follow-up information will be obtained via telephone interviews and outpatient clinical visits. The telephone interview follow-up information includes ambulation improvements, current medication, smoking status, wound healing (if necessary), rehospitalization and quality of life. Outpatient clinical visit follow-up information includes ABI, Rutherford classification, vascular ultrasound, the need for reintervention and the presence of new-onset lesions.

These relevant details will also be recorded in the CRF and transferred into electronic records in the lower extremity artery data management system. All centres participating in this study will have access to the data. The participant’s personal information will be encrypted to prevent leakage. All the participants will undergo follow-up at 1, 6, 12, 18 and 24 months after the operation.

**Outcome measures**

The primary outcome of the study is freedom from clinically driven TLR at 24 months. CD-TLR is defined as any reintervention within the target lesion(s) because of recurrent symptoms. Freedom from CD-TLR is defined as the rate of the number of patients who did not receive reintervention versus the number of patients during the follow-up period.<sup>13 14</sup> The secondary outcomes include 1) primary patency, which was defined as the percentage of stent patency examined by DUS or CTA examination during follow-up; 2) technical success rate; 3) incidence of major adverse events; 4) freedom from CD-TLR at 1, 6, 12 and 18 months; 5) assessment using The Vascular

1 Quality of Life Questionnaire (VascuQol), which contains five domains to evaluate  
2 health-related quality of life (HRQL), including pain (4 items), symptoms (4 items),  
3 activities (8 items), social (2 items), and emotional (7 items); and 6) health economics  
4 evaluation, which is defined as all the costs related to the target vessel  
5 revascularization in the inpatient ward.

## 6 **Adverse events**

7 The adverse events will be categorized into minor and major adverse events, and  
8 the frequency of minor and major adverse events during the treatment period and  
9 follow-up period will both be recorded. The minor adverse events included arterial  
10 puncture complications, distal embolism without clinical manifestations,  
11 postoperative thrombosis without critical limb ischemia, and reversible contrast  
12 induced nephropathy. In addition, major adverse events include major amputation  
13 related to endovascular treatment, cardio- and cerebrovascular events, arterial  
14 puncture complications requiring intervention, progressive haemoglobin disease,  
15 acute renal failure and death. Once adverse events are identified, the corresponding  
16 centres will actively manage and report the adverse events. The adverse events and  
17 the process of treatment will be documented and reported to the corresponding ethics  
18 committee. Once death events occur, the corresponding centres and the participating  
19 investigator should immediately provide all necessary information to the ethics  
20 committee.

## 22 **Sample size and statistical analysis**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1        Taking into account a 10% lost to follow-up rate and a target enrolment of 300  
2 patients, 270 patients will be included in the effectiveness analysis.

3        Statistical analysis will be performed using Stata SE 15.1 software (Stata Corp,  
4 College Station, TX, USA). Continuous data will be presented as the mean  $\pm$  standard  
5 deviation, and categorical data will be presented as numbers (n) and percentages (%).

6        Normal distribution and homogeneous tests of variance will be performed in  
7 advance. For the data groups that have a normal distribution and homogeneous  
8 variances, comparisons between two groups will be made using unpaired Student's t  
9 tests and one-way ANOVA followed by Bonferroni tests for multiple group  
10 comparisons. For the data groups that do not have a normal distribution or  
11 homogeneous variances, nonparametric tests will be used. Univariate and multivariate  
12 analyses will be performed by logistic analysis. Generally, a two-sided *P* value < 0.05  
13 will be considered statistically significant unless otherwise stated.

14  
15        **Discussion**

16        The FP-RESTORE will be the first study to provide prospective data on the  
17 effectiveness, safety and health economics evaluation of different endovascular  
18 modalities in the treatment of Tosaka III FP-ISR in a real-world setting. The  
19 endovascular treatments employed in FP-ISR include BA alone, DCB, cutting  
20 balloon, BMS, covered stent, mechanical debulking devices, laser atherectomy or a  
21 combination of the above.<sup>13-25</sup> However, the methods and results widely vary, which  
22 makes it difficult to compare the outcomes and make valid conclusions. FP-

1 RESTORE is thus designed to evaluate and compare these endovascular procedures  
2 for Tosaka III FP-ISR. We hope our results will provide useful information and  
3 guidance about this issue and references for future controlled studies.

4 Clinically driven freedom from TLR is the primary outcome in our study. On the  
5 one hand, FP-RESTORE is designed to pay more attention to the clinical efficacy of  
6 various endovascular modalities; thus, clinically driven freedom from TLR could  
7 reflect the clinical effectiveness more intuitively. On the other hand, the inclusion  
8 criteria in real-world settings are not as strict as those of controlled studies; thus, a  
9 broader range of patients could be enrolled. Given that the patients are recruited  
10 throughout China, the imaging follow-up rate at different centres will vary widely,  
11 which may lead to missing information regarding primary patency. Thus, clinically  
12 driven freedom from TLR will serve as the primary outcome, whereas primary  
13 patency and other results will serve as secondary outcomes in this study.

#### 14 **Ethics and dissemination**

15 The study protocol was approved by the Institutional Review Board and Human  
16 Research Ethics Committee of Zhongshan Hospital, Fudan University (B2021-427).  
17 All the patients will be informed of their voluntary participation and provide written  
18 informed consent. The trial protocol complies with the Declaration of Helsinki.

19 The study outcomes will be disseminated by publication in a peer-reviewed  
20 journal. The relevant confidential information will be transferred into a specific code  
21 to avoid potential leakage. In addition, the trial design has also been registered at  
22 ClinicalTrials.gov (Number: NCT04801004).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Author Contributions:** The authors have been included in this manuscript based on the ICMJE recommendations. XL, MZ, YD, and ZS planned and designed the study. MY and ZW reviewed the structure of this manuscript. XL, MY, ZW ZF, LG, QL, XF and HS contributed to patient enrolment and collection of patient data. ZS critically reviewed and approved this manuscript. All authors have read and approved the final manuscript.

**Funding:** This work was supported by the National Natural Science Foundation of China (Grant number: 81870342 from ZS).

**Acknowledgements:** None

**Competing interests:** None

**Patient informed consent:** Obtained

**Ethics approval:** The study protocol was approved by the Institutional Review Board and Human Research Ethics Committee of Zhongshan Hospital, Fudan University (B2021-427).

**Provenance and peer review:** Not commissioned; externally peer reviewed.

**Data sharing:** No additional data are available.

**References**

1. Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. *Lancet* 2013;382(9901):1329-40.

2. Ho KJ, Owens CD. Diagnosis, classification, and treatment of femoropopliteal

- 1 artery in-stent restenosis. *J Vasc Surg* 2017;65(2):545-57.
- 2 3. Shamma NW, Jones-Miller S, Lemke J. Meta-Analysis-Derived Benchmarks of
- 3 Patency and Target Lesion Revascularization of Percutaneous Balloon Angioplasty
- 4 from Prospective Clinical Trials of Symptomatic Femoropopliteal In-Stent
- 5 Restenosis. *J Vasc Interv Radiol* 2016;27(8):1195-203.
- 6 4. Tosaka A, Soga Y, Iida O, et al. Classification and clinical impact of restenosis
- 7 after femoropopliteal stenting. *J Am Coll Cardiol* 2012;59(1):16-23.
- 8 5. Armstrong EJ, Singh S, Singh GD, et al. Angiographic characteristics of
- 9 femoropopliteal in-stent restenosis: association with long-term outcomes after
- 10 endovascular intervention. *Catheter Cardiovasc Interv* 2013;82(7):1168-74.
- 11 6. Giannopoulos S, Kokkinidis DG, Jawaid O, et al. Turbo-Power Laser Atherectomy
- 12 Combined with Drug-coated Balloon Angioplasty is Associated with Improved One-
- 13 Year Outcomes for the Treatment of Tosaka II and III Femoropopliteal In-stent
- 14 Restenosis. *Cardiovasc Revasc Med* 2020;21(6):771-78.
- 15 7. Zhang B, Niu G, Yan Z, et al. Drug-Coated Balloon for the Treatment of
- 16 Femoropopliteal Tosaka Class III In-stent Restenosis Lesions. *Front Surg*
- 17 2020;7:616414.
- 18 8. Li X, Zhou M, Ding Y, et al. A systematic review and meta-analysis of the efficacy
- 19 of debulking devices for in-stent restenosis of the femoropopliteal artery. *J Vasc Surg*
- 20 2020;72(1):356-66 e5.
- 21 9. Beschorner U, Krankenberg H, Scheinert D, et al. Rotational and aspiration
- 22 atherectomy for infrainguinal in-stent restenosis. *Vasa* 2013;42(2):127-33.

10. Shamma NW, Coiner D, Shamma GA, et al. Percutaneous lower-extremity arterial interventions with primary balloon angioplasty versus Silverhawk atherectomy and adjunctive balloon angioplasty: randomized trial. *J Vasc Interv Radiol* 2011;22(9):1223-8.
11. Sixt S, Carpio Cancino OG, Treszl A, et al. Drug-coated balloon angioplasty after directional atherectomy improves outcome in restenotic femoropopliteal arteries. *J Vasc Surg* 2013;58(3):682-6.
12. Trentmann J, Charalambous N, Djawanscher M, et al. Safety and efficacy of directional atherectomy for the treatment of in-stent restenosis of the femoropopliteal artery. *J Cardiovasc Surg (Torino)* 2010;51(4):551-60.
13. Dippel EJ, Makam P, Kovach R, et al. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCimer Laser Randomized Controlled Study for Treatment of Femoropopliteal In-Stent Restenosis). *JACC Cardiovasc Interv* 2015;8(1 Pt A):92-101.
14. Torsello G, Stavroulakis K, Brodmann M, et al. Three-Year Sustained Clinical Efficacy of Drug-Coated Balloon Angioplasty in a Real-World Femoropopliteal Cohort. *J Endovasc Ther* 2020;27(5):693-705.
15. Beschoner U, Zeller T. Combination of mechanical atherectomy and drug-eluting balloons for femoropopliteal in-stent restenosis. *J Cardiovasc Surg (Torino)* 2014;55(3):347-9.
16. Dick P, Sabeti S, Mlekusch W, et al. Conventional balloon angioplasty versus

- 1 peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent  
2 restenosis: initial experience. *Radiology* 2008;248(1):297-302.
- 3 17. Gandini R, Del Giudice C, Merolla S, et al. Treatment of chronic SFA in-stent  
4 occlusion with combined laser atherectomy and drug-eluting balloon angioplasty in  
5 patients with critical limb ischemia: a single-center, prospective, randomized study. *J*  
6 *Endovasc Ther* 2013;20(6):805-14.
- 7 18. Kokkinidis DG, Behan S, Jawaid O, et al. Laser atherectomy and drug-coated  
8 balloons for the treatment of femoropopliteal in-stent restenosis: 2-Year outcomes.  
9 *Catheter Cardiovasc Interv* 2020;95(3):439-46.
- 10 19. Laird JR, Jr., Yeo KK, Rocha-Singh K, et al. Excimer laser with adjunctive  
11 balloon angioplasty and heparin-coated self-expanding stent grafts for the treatment  
12 of femoropopliteal artery in-stent restenosis: twelve-month results from the  
13 SALVAGE study. *Catheter Cardiovasc Interv* 2012;80(5):852-9.
- 14 20. Murata N, Takahara M, Soga Y, et al. Drug-Eluting Stent vs Percutaneous  
15 Transluminal Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis:  
16 Results From a Retrospective 1-Year Multicenter Study. *J Endovasc Ther*  
17 2016;23(4):642-7.
- 18 21. Shammass NW, Shammass GA, Banerjee S, et al. JetStream Rotational and  
19 Aspiration Atherectomy in Treating In-Stent Restenosis of the Femoropopliteal  
20 Arteries: Results of the JETSTREAM-ISR Feasibility Study. *J Endovasc Ther*  
21 2016;23(2):339-46.
- 22 22. Shammass NW, Shammass GA, Hafez A, et al. Safety and One-Year



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 revascularization outcome of excimer laser ablation therapy in treating in-stent  
2 restenosis of femoropopliteal arteries: A retrospective review from a single center.  
3 *Cardiovasc Revasc Med* 2012;13(6):341-4.  
4 23. Shammass NW, Shammass GA, Helou TJ, et al. Safety and 1-year revascularization  
5 outcome of SilverHawk atherectomy in treating in-stent restenosis of femoropopliteal  
6 arteries: a retrospective review from a single center. *Cardiovasc Revasc Med*  
7 2012;13(4):224-7.  
8 24. van den Berg JC, Pedrotti M, Canevascini R, et al. In-stent restenosis: mid-term  
9 results of debulking using excimer laser and drug-eluting balloons: sustained benefit?  
10 *J Invasive Cardiol* 2014;26(7):333-7.  
11 25. Zeller T, Dake MD, Tepe G, et al. Treatment of femoropopliteal in-stent  
12 restenosis with paclitaxel-eluting stents. *JACC Cardiovasc Interv* 2013;6(3):274-81.  
13

# Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. BMJ. 2013;346:e7586

			Page Number
Reporting Item			
<b>Administrative information</b>			
Title	<a href="#">#1</a>	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	<a href="#">#2a</a>	Trial identifier and registry name. If not yet registered, name of intended registry	4
Trial registration: data set	<a href="#">#2b</a>	All items from the World Health Organization Trial Registration Data Set	5
Protocol version	<a href="#">#3</a>	Date and version identifier	5
Funding	<a href="#">#4</a>	Sources and types of financial, material, and other support	15
Roles and responsibilities: contributorship	<a href="#">#5a</a>	Names, affiliations, and roles of protocol contributors	1-2

1	Roles and	<a href="#">#5b</a>	Name and contact information for the trial sponsor	n/a
2	responsibilities:			
3	sponsor contact			
4	information			
5				
6				
7				
8	Roles and	<a href="#">#5c</a>	Role of study sponsor and funders, if any, in study design;	n/a
9	responsibilities:		collection, management, analysis, and interpretation of data;	
10	sponsor and funder		writing of the report; and the decision to submit the report for	
11			publication, including whether they will have ultimate authority	
12			over any of these activities	
13				
14				
15				
16	Roles and	<a href="#">#5d</a>	Composition, roles, and responsibilities of the coordinating centre,	15
17	responsibilities:		steering committee, endpoint adjudication committee, data	
18	committees		management team, and other individuals or groups overseeing the	
19			trial, if applicable (see Item 21a for data monitoring committee)	
20				
21				
22				
23	<b>Introduction</b>			
24				
25	Background and	<a href="#">#6a</a>	Description of research question and justification for undertaking	5-7
26	rationale		the trial, including summary of relevant studies (published and	
27			unpublished) examining benefits and harms for each intervention	
28				
29				
30				
31	Background and	<a href="#">#6b</a>	Explanation for choice of comparators	7
32	rationale: choice of			
33	comparators			
34				
35				
36	Objectives	<a href="#">#7</a>	Specific objectives or hypotheses	6
37				
38	Trial design	<a href="#">#8</a>	Description of trial design including type of trial (eg, parallel	7
39			group, crossover, factorial, single group), allocation ratio, and	
40			framework (eg, superiority, equivalence, non-inferiority,	
41			exploratory)	
42				
43				
44				
45	<b>Methods:</b>			
46	<b>Participants,</b>			
47	<b>interventions, and</b>			
48	<b>outcomes</b>			
49				
50				
51				
52	Study setting	<a href="#">#9</a>	Description of study settings (eg, community clinic, academic	7
53			hospital) and list of countries where data will be collected.	
54			Reference to where list of study sites can be obtained	
55				
56				
57	Eligibility criteria	<a href="#">#10</a>	Inclusion and exclusion criteria for participants. If applicable,	8-9
58			eligibility criteria for study centres and individuals who will	
59				
60				

		perform the interventions (eg, surgeons, psychotherapists)	
Interventions: description	<a href="#">#11a</a>	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	10
Interventions: modifications	<a href="#">#11b</a>	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	9-10
Interventions: adherence	<a href="#">#11c</a>	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	11
Interventions: concomitant care	<a href="#">#11d</a>	Relevant concomitant care and interventions that are permitted or prohibited during the trial	11-12
Outcomes	<a href="#">#12</a>	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	12
Participant timeline	<a href="#">#13</a>	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	12
Sample size	<a href="#">#14</a>	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	13
Recruitment	<a href="#">#15</a>	Strategies for achieving adequate participant enrolment to reach target sample size	11
<b>Methods: Assignment of interventions (for controlled trials)</b>			
Allocation: sequence generation	<a href="#">#16a</a>	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	n/a

1	Allocation concealment	<a href="#">#16b</a>	Mechanism of implementing the allocation sequence (eg, central	n/a
2	mechanism		telephone; sequentially numbered, opaque, sealed envelopes),	
3			describing any steps to conceal the sequence until interventions are	
4			assigned	
5				
6				
7				
8	Allocation:	<a href="#">#16c</a>	Who will generate the allocation sequence, who will enrol	n/a
9	implementation		participants, and who will assign participants to interventions	
10				
11	Blinding (masking)	<a href="#">#17a</a>	Who will be blinded after assignment to interventions (eg, trial	n/a
12			participants, care providers, outcome assessors, data analysts), and	
13			how	
14				
15				
16				
17	Blinding (masking):	<a href="#">#17b</a>	If blinded, circumstances under which unblinding is permissible,	n/a
18	emergency unblinding		and procedure for revealing a participant’s allocated intervention	
19			during the trial	
20				
21				
22	<b>Methods: Data</b>			
23	<b>collection,</b>			
24	<b>management, and</b>			
25	<b>analysis</b>			
26				
27				
28				
29	Data collection plan	<a href="#">#18a</a>	Plans for assessment and collection of outcome, baseline, and other	11
30			trial data, including any related processes to promote data quality	
31			(eg, duplicate measurements, training of assessors) and a	
32			description of study instruments (eg, questionnaires, laboratory	
33			tests) along with their reliability and validity, if known. Reference	
34			to where data collection forms can be found, if not in the protocol	
35				
36				
37				
38				
39	Data collection plan:	<a href="#">#18b</a>	Plans to promote participant retention and complete follow-up,	11
40	retention		including list of any outcome data to be collected for participants	
41			who discontinue or deviate from intervention protocols	
42				
43				
44	Data management	<a href="#">#19</a>	Plans for data entry, coding, security, and storage, including any	11
45			related processes to promote data quality (eg, double data entry;	
46			range checks for data values). Reference to where details of data	
47			management procedures can be found, if not in the protocol	
48				
49				
50				
51	Statistics: outcomes	<a href="#">#20a</a>	Statistical methods for analysing primary and secondary outcomes.	13
52			Reference to where other details of the statistical analysis plan can	
53			be found, if not in the protocol	
54				
55				
56	Statistics: additional	<a href="#">#20b</a>	Methods for any additional analyses (eg, subgroup and adjusted	14
57	analyses		analyses)	
58				
59				
60				

Statistics: analysis population and missing data	<a href="#">#20c</a>	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	14
<b>Methods: Monitoring</b>			
Data monitoring: formal committee	<a href="#">#21a</a>	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	n/a
Data monitoring: interim analysis	<a href="#">#21b</a>	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	n/a
Harms	<a href="#">#22</a>	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	n/a
Auditing	<a href="#">#23</a>	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	n/a
<b>Ethics and dissemination</b>			
Research ethics approval	<a href="#">#24</a>	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	15
Protocol amendments	<a href="#">#25</a>	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	15
Consent or assent	<a href="#">#26a</a>	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	15
Consent or assent: ancillary studies	<a href="#">#26b</a>	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	15
Confidentiality	<a href="#">#27</a>	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	11

1	Declaration of interests	<a href="#">#28</a>	Financial and other competing interests for principal investigators for the overall trial and each study site	15
2				
3				
4				
5	Data access	<a href="#">#29</a>	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	11
6				
7				
8				
9				
10	Ancillary and post trial	<a href="#">#30</a>	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a
11	care			
12				
13				
14	Dissemination policy:	<a href="#">#31a</a>	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	15
15	trial results			
16				
17				
18				
19				
20				
21	Dissemination policy:	<a href="#">#31b</a>	Authorship eligibility guidelines and any intended use of professional writers	15
22	authorship			
23				
24				
25	Dissemination policy:	<a href="#">#31c</a>	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	15
26	reproducible research			
27				
28				
29	<b>Appendices</b>			
30				
31	Informed consent	<a href="#">#32</a>	Model consent form and other related documentation given to participants and authorised surrogates	n/a
32	materials			
33				
34				
35	Biological specimens	<a href="#">#33</a>	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a
36				
37				
38				
39				

40 The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative Commons  
41 Attribution License CC-BY-NC. This checklist was completed on 10. December 2021 using  
42 <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59



# BMJ Open

## Design of the FP-RESTORE study: A protocol for prospective, observational study of real-world treatments with endovascular therapy in patients with femoropopliteal artery Tosaka III in-stent restenosis.

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-060200.R2
Article Type:	Protocol
Date Submitted by the Author:	19-Aug-2022
Complete List of Authors:	<p>Li, Xu; Zhongshan Hospital Fudan University, Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine</p> <p>Zhou, Min; Zhongshan Hospital Fudan University, Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine</p> <p>Ding, Yong; Zhongshan Hospital Fudan University, Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine</p> <p>Wu, Ziheng; Zhejiang University School of Medicine First Affiliated Hospital, Department of Vascular Surgery</p> <p>Feng, Zibo; Liyuan Hospital of Tongji Medical College of Huazhong University of Science and Technology, Department of Vascular Surgery</p> <p>guo, Lianrui; Xuanwu Hospital Capital Medical University, Department of Vascular Surgery</p> <p>Li, Qiang; Qingdao Haici Hospital, Department of Vascular Surgery</p> <p>Fang, Xin; Affiliated Hangzhou First People's Hospital Zhejiang University School of Medicine, Department of Vascular Surgery</p> <p>Sang, Hongfei; Second Affiliated Hospital of Soochow University, Department of Vascular Surgery</p> <p>Ye, Meng; Shanghai Jiaotong University, Department of Vascular Surgery</p> <p>Shi, Zhenyu; Zhongshan Hospital Fudan University, Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine</p>
<b>Primary Subject Heading</b>:	Surgery
Secondary Subject Heading:	Surgery
Keywords:	Interventional radiology < RADIOLOGY & IMAGING, Vascular surgery < SURGERY, Clinical trials < THERAPEUTICS





1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Design of the FP-RESTORE study: A protocol for prospective, observational study of real-world treatments with endovascular therapy in patients with femoropopliteal artery Tosaka III in-stent restenosis.**

**AUTHORS :**

**Xu Li**, Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine, Shanghai, China. **E-mail:** [lixu007qq@163.com](mailto:lixu007qq@163.com)

**Min Zhou**, Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine, Shanghai, China. E-mail: [med-zhou@foxmail.com](mailto:med-zhou@foxmail.com)

**Yong Ding**, Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine, Shanghai, China. E-mail: [Med.YoungDee@gmail.com](mailto:Med.YoungDee@gmail.com)

**Ziheng Wu**, Department of Vascular Surgery, the First Affiliated hospital of Medicine College of Zhejiang University, Hangzhou, China. E-mail: [wuziheng@zju.edu.cn](mailto:wuziheng@zju.edu.cn).

**Zibo Feng**, Department of Vascular Surgery, Liyuan Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan, China E-mail: [390306820@qq.com](mailto:390306820@qq.com)

**Lianrui Guo**, Department of Vascular Surgery, Xuanwu Hospital Capital Medical

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 University, Beijing, China E-mail: [lianruiguo@sina.com](mailto:lianruiguo@sina.com)

2 **Qiang Li**, Department of Vascular Surgery, Qingdao Haici hospital affiliated to

3 Qingdao University, Qingdao, China E-mail: [haicixueguan@163.com](mailto:haicixueguan@163.com)

4 **Xin Fang**, Department of Vascular Surgery, Hangzhou First People’s hospital of

5 Medical College of Zhejiang University, Hangzhou, China. E-mail: [hzfhfx@126.com](mailto:hzfhfx@126.com)

6 **Hongfei Sang**, Department of Vascular Surgery, the second Affiliated Hospital of

7 Medical College of Suzhou University, Suzhou, China. [sanghf@yahoo.com.cn](mailto:sanghf@yahoo.com.cn)

8 **Meng Ye\***, Department of Vascular Surgery, Renji Hospital, School of Medicine,

9 Shanghai Jiaotong University, Shanghai, China. Email:

10 [doctor\\_yemeng2018@163.com](mailto:doctor_yemeng2018@163.com)

11 **Zhenyu Shi\***, Department of Vascular Surgery, Zhongshan Hospital, Institute of

12 Vascular Surgery, Fudan University, National Clinical Research Center for

13 Interventional Medicine, Shanghai, China. E-mail: [shizhenyumax@163.com](mailto:shizhenyumax@163.com)

14

15 Xu Li\* and Min Zhou\* contribute to this work equally.

16 **Word count, total:** 2442

17 **Word count, abstract:**243

18 **CORRESPONDING AUTHOR:**

19 Zhenyu Shi, MD, PhD

20 Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery,

21 Fudan University, National Clinical Research Center for Interventional Medicine,

22 Shanghai, China.

1 180 Fenglin Road, 200032, Shanghai, China

2 &

3 Meng Ye, MD, PhD

4 Department of Vascular Surgery, Renji Hospital, School of Medicine, Shanghai

5 Jiaotong University

6 Pujian Road 160, Shanghai 200127, China.

7 Email: doctor\_yemeng2018@163.com

8 Tel.: 8621-6404-1990 ext. 2359

9 Fax: 8621-6443-2410

10 E-mail address: shizhenyumax@163.com

11

12

13

14

15

16

17

18

19

20

21

22

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Abstract**

**Introduction:** Femoropopliteal artery in-stent restenosis (FP-ISR) represents one of the main obstacles for stent implantation in PAD patients, especially Tosaka III FP-ISR, which is also referred to as in-stent occlusion. Diverse endovascular treatments of Tosaka III FP-ISR are available, and the results are unequivocal. However, real-world data are limited. This study aims to evaluate the efficacy, safety and health economics evaluation of various endovascular procedures in the treatment of Tosaka III FP-ISR.

**Method and analysis**

This study is a prospective, multicentre, real-world, observational clinical study. Patients diagnosed with Tosaka III FP-ISR and treated with endovascular procedures in 9 centres from 1 April 2021 to 31 December 2022 will be recruited. The relevant clinical information, ankle-brachial index and CT angiography will be collected. All the participants will undergo follow-up at 1, 6, 12, 18 and 24 months after the operation. The primary outcome is freedom from clinically driven target lesion revascularization (CD-TLR) at 24 months. Safety and health economics issues will also be reported.

**Ethics and dissemination**

The FP-RESTORE clinical trial has been registered at ClinicalTrials.gov (<http://clinicaltrials.gov/>). This study was also approved by the Institutional Review Board and Human Research Ethics Committee of Zhongshan Hospital, Fudan

1 University (approval number: B2021-427). Moreover, written informed consent will  
2 be obtained at the time of recruitment. The study outcomes will be disseminated by  
3 publication in a peer-reviewed journal to provide information for further clinical  
4 practice.

5 **Trial registration number:** NCT04801004.

6 **Protocol version and date:** V.1.1, 1 April 2021.

### 7 8 9 **Strengths and limitations of this study**

- 10 1. This study is a prospective, multicentre, real-world, observational clinical study.
- 11 2. This study focuses on the efficacy, safety and health economics evaluation of
- 12 various endovascular operations in the treatment of Tosaka III FP-ISR.
- 13 3. This is an observational study, and no interference with endovascular treatments
- 14 will occur.
- 15 4. The revascularization of Tosaka III FP-ISR is associated with poor outcomes.

### 16 17 **Introduction:**

18 The femoropopliteal artery is one of most commonly treated peripheral artery  
19 diseases (PAD).<sup>1</sup> The treatment modalities mainly include conservative treatment,  
20 endovascular procedures and surgical operations, with endovascular treatment being  
21 more widely applied. However, femoropopliteal artery in-stent restenosis (FP-ISR)  
22 has become one of the main blocks for stent implantation in PAD patients with high

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 morbidity, especially Tosaka III in-stent restenosis, which is also referred to as in-  
2 stent obstruction.<sup>2 3</sup> Tosaka et al. reported that the freedom from recurrent ISR at 12  
3 months was 22.7% for Tosaka III lesions compared with 72.5% and 65.6% for Tosaka  
4 I and II lesions, respectively.<sup>4</sup> Armstrong et al. reported that the freedom from  
5 recurrent restenosis at 24 months was 28% for Tosaka III lesions compared with 61%  
6 and 34% for TOSAKA I and II lesions, respectively.<sup>5</sup> This finding indicated that in-  
7 stent occlusion correlated with a worse prognosis than in-stent restenosis.

8       Giannopoulos et al. reported freedom from TLR of 88.9% in the laser debulking  
9 devices (LD) + drug coated balloons (DCB) group compared with 54.2% in the LD +  
10 balloon angioplasty (BA) group in a 12-month estimate for the treatment of Tosaka III  
11 FP-ISR.<sup>6</sup> Zhang et al. reported the results of DCB in the treatment of Tosaka III FP-  
12 ISR with primary patency and freedom from TLR estimates of 79.2% and 91.5%,  
13 respectively, at the 14-month follow-up.<sup>7</sup> Debulking devices (laser debulking or  
14 mechanical debulking devices) have also been widely used in the treatment of FP-  
15 ISR. Our previous meta-analysis demonstrated that patients with long and occlusive  
16 ISR lesions benefit more from debulking devices.<sup>8</sup> Previous studies have also reported  
17 roles for mechanical atherothrombectomy in the treatment of Tosaka III in-stent  
18 restenosis with freedom from TLR at 12 months ranging from 43.8% to 84.7%.<sup>9-12</sup>  
19 Given that the outcomes for endovascularly treated Tosaka III FP-ISR varied, there is  
20 a need for data from a real-world setting to evaluate the safety, efficacy and economic  
21 cost of different endovascular modalities in the treatment of Tosaka III FP-ISR. In a  
22 real-world setting, the trial could recruit patients with in-stent occlusion rather than

1 mild in-stent restenosis lesions.

2 Although there have been clinical reports about the preliminary and midterm  
3 stage results of different endovascular treatments in the treatment of Tosaka III FP-  
4 ISR patients, these results were still insufficient to reflect real-world clinical practice.  
5 Thus, we initiated a clinical trial named the FP-RESTORE study to examine the  
6 safety, effectiveness and economic cost of different endovascular therapies in the  
7 treatment of Tosaka III FP-ISR patients in a real-world setting across China.

## 8 **METHODS**

### 9 **Study design**

10 FP-RESTORE is a prospective, multicentre, real-world, observational clinical study  
11 that aims to evaluate the safety, efficacy and economic cost of different endovascular  
12 therapies in Tosaka III (totally occluded) in-stent restenosis. It is estimated that 300  
13 subjects diagnosed with femoropopliteal artery Tosaka III in-stent restenosis and  
14 receiving endovascular treatments will be enrolled in nine centres from April 2021 to  
15 December 2022 nationwide in China. No restrictions on the endovascular techniques  
16 used will be employed to make it easier to compare the effects of different  
17 endovascular treatments in Tosaka III in-stent restenosis.

18 The main purpose is to observe the freedom from clinically driven target lesion  
19 revascularization (CD-TLR), primary patency, the improvement in quality-of-life  
20 score, and health economics evaluation.

21 The study was designed and initiated by the Department of Vascular Surgery,  
22 Zhongshan Hospital, Fudan University. No patient or public involvement is required.



**Participants**

To minimize bias in the selection of patients, investigators at participating sites are encouraged to enroll all eligible Tosaka III in-stent restenosis patients receiving endovascular treatments. The patients will be screened for enrolment from April 2021 to December 2022 in nine designated centres across China. A total of 300 patients who received stent implantation to treat PAD and developed Tosaka III FP-ISR will be recruited. Recruitment is non-competitive and will not affect clinical practice.

**CRITERIA**

**Inclusion criteria**

- 1. Tosaka III In-stent restenosis after stent implantation in PAD patients (Including acute and subacute thrombotic lesions).
- 2. Rutherford grade 2-5.
- 3. Stents should be located in the femoropopliteal artery.
- 4. The stenosis of iliac artery on the affected side is less than 30% or the residual stenosis after treatment is less than 30%.
- 5. Informed consent has been signed

**Exclusion criteria**

- 1. Tosaka I or II in-stent restenosis.
- 2. Stents are located in iliac artery or artery below the knee, or the preoperative CTA showed type 3 or 4 stent fracture.
- 3. Rutherford Grade 6.
- 4. Thromboangiitis obliterans (TAO)-based, arteritis-based or connective tissue

1 disorder-based FP-ISR.

2 5. Intraoperative conversion to hybrid or open surgery.

3 6. Patients refusing to sign informed consent forms.

4 7. Life expectancy of patients is less than 12 months.

5 8. The pregnant or nursing patients.

6 9. The patients with severe ischemia of lower extremity who would receive major  
7 amputation in plan.

8 10. Patients in whom antiplatelet or anticoagulant therapy is contraindicated.

9 11. Myocardial infarction or stroke within 3 months prior to enrolment.

10 12. Patient with known allergy to contrast agents or medications used to perform  
11 endovascular intervention.

12 13. Patients participating in another research study involving an investigational agent  
13 (pharmaceutical, biologic, or medical device) that has not reached the primary  
14 endpoint.

15 14. Patients who refuse to cooperate with long-term follow-up or who have difficulty  
16 communicating.

17

## 18 **Criteria for discontinuing**

19 Subjects could discontinue participation in this trial at any time for any reason without  
20 any consequences. In addition, the investigators could decide whether the patient is  
21 excluded from the study depending on the following conditions.

22 1. The patients are lost to follow-up.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1     2. The patients voluntarily withdraw their informed consent.
- 2     3. In case of serious violation of the study protocol by investigators or subjects.
- 3     4. Patient is simultaneously participating in another investigational drug or device
- 4     study.
- 5     5. Patient has any planned surgical or interventional procedure within 30 days after the
- 6     study procedure.
- 7     Once the subject discontinued participation in the trial, his or her relevant primary
- 8     outcomes and secondary outcomes would be eliminated.

10     **Endovascular procedure**

11         All enrolled patients will be treated with endovascular therapies. In general,

12     endovascular approaches are established from the contralateral common femoral

13     artery or the ipsilateral common femoral artery or a brachial approach. Retrograde

14     puncture access via the popliteal artery will be chosen once intervention with the

15     antegrade approach is unsuccessful. Angiography will be performed to assess the

16     lesion severity, length and location. Then, angiography of the target artery will be

17     performed, and the guide wire will be passed through the in-stent occlusion lesion.

18     Then, multiple types of endovascular treatments, including BA, DCB, drug eluting

19     stent (DES) implantation, bare metal stent (BMS) implantation, intravascular

20     lithotripsy, directional atherectomy, laser debulking, stent-graft implantation or a

21     combination of the above, will be applied according to the characteristics of the lesion

22     and physician preferences. Generally, BA and DCB will be used as the basis for

1 endovascular treatment of FR-ISR. Thrombectomy devices will be applied in acute or  
2 subacute thrombosis lesions, and both laser debulking devices and atherectomy  
3 debulking devices are preferred in chronic long lesions. The devices used  
4 intraoperatively will be based on the operator's preferences. Final angiography will be  
5 performed to assess the efficacy of endovascular treatment. Residual stenosis of less  
6 than 30% will be defined as technical success.

### 8 **Recruitment**

9 All suitable patients will receive a routine examination during admission. Patients  
10 will receive intraoperative angiography of lower extremity artery, and data on the  
11 lesion length, stenosis degree, extent of lesion, collateral circulation will be assessed.  
12 Moreover, eligible patients will be enrolled after signing the informed consent form.

### 13 **Data collection**

14 A standard case report form (CRF) has been established at the beginning of this study.  
15 This CRF will collect the patients' quality of life (QoL), systemic disease history,  
16 perioperative risk factor assessment, clinical symptom classification, lesion location  
17 and Trans-Atlantic Inter-Society Consensus II (TASC) classification, endovascular  
18 procedure details, treatment outcomes and complications as well as follow-up  
19 information. Two investigators will perform the data input independently, and data  
20 input verification will be conducted to reduce the chance of error. The original CRF  
21 will be archived by the sponsor, and a copy of the CRF will be kept at the centre and  
22 transferred into electronic records in a correlated data management system. This

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 system covers preoperative assessment, intraoperative details and follow-up  
2 information.

3

4 **Surveillance and follow-up**

5 Follow-up will be coordinated by each participating centre independently. The  
6 follow-up information will be obtained via telephone interviews and outpatient  
7 clinical visits. The telephone interview follow-up information includes ambulation  
8 improvements, current medication, smoking status, wound healing (if necessary),  
9 rehospitalization and quality of life. Outpatient clinical visit follow-up information  
10 includes ABI, Rutherford classification, vascular ultrasound, the need for  
11 reintervention and the presence of new-onset lesions.

12 These relevant details will also be recorded in the CRF and transferred into  
13 electronic records in the lower extremity artery data management system. All centres  
14 participating in this study will have access to the data. The participant’s personal  
15 information will be encrypted to prevent leakage. All the participants will undergo  
16 follow-up at 1, 6, 12, 18 and 24 months after the operation.

17 **Outcome measures**

18 The primary outcome of the study is freedom from clinically driven TLR at 24  
19 months. CD-TLR is defined as any reintervention within the target lesion(s) because  
20 of recurrent symptoms. Freedom from CD-TLR is defined as the rate of the number of  
21 patients who did not receive reintervention versus the number of patients during the  
22 follow-up period.<sup>13 14</sup> The secondary outcomes include 1) primary patency, which was

defined as the percentage of stent patency examined by DUS or CTA examination during follow-up; 2) technical success rate; 3) incidence of major adverse events; 4) freedom from CD-TLR at 1, 6, 12 and 18 months; 5) assessment using The Vascular Quality of Life Questionnaire (VascuQol), which contains five domains to evaluate health-related quality of life (HRQL), including pain (4 items), symptoms (4 items), activities (8 items), social (2 items), and emotional (7 items); and 6) health economics evaluation, which is defined as all the costs related to the target vessel revascularization in the inpatient ward. Moreover, the health economics evaluation of technique failed participants will also be included.

#### **Adverse events**

The adverse events will be categorized into minor and major adverse events, and the frequency of minor and major adverse events during the treatment period and follow-up period will both be recorded. The minor adverse events included arterial puncture complications, distal embolism without clinical manifestations, postoperative thrombosis without critical limb ischemia, and reversible contrast induced nephropathy. In addition, major adverse events include major amputation related to endovascular treatment, cardio- and cerebrovascular events, arterial puncture complications requiring intervention, progressive haemoglobin disease, acute renal failure and death. Once adverse events are identified, the corresponding centres will actively manage and report the adverse events. The adverse events and the process of treatment will be documented and reported to the corresponding ethics committee. Once death events occur, the corresponding centres and the participating

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

investigator should immediately provide all necessary information to the ethics committee.

**Sample size and statistical analysis**

Taking into account a 10% lost to follow-up rate and a target enrolment of 300 patients, 270 patients will be included in the effectiveness analysis.

Statistical analysis will be performed using Stata SE 15.1 software (Stata Corp, College Station, TX, USA). Continuous data will be presented as the mean ± standard deviation, and categorical data will be presented as numbers (n) and percentages (%).

Normal distribution and homogeneous tests of variance will be performed in advance. For the data groups that have a normal distribution and homogeneous variances, comparisons between two groups will be made using unpaired Student's t tests and one-way ANOVA followed by Bonferroni tests for multiple group comparisons. For the data groups that do not have a normal distribution or homogeneous variances, nonparametric tests will be used. Univariate and multivariate analyses will be performed by logistic analysis. Generally, a two-sided *P* value < 0.05 will be considered statistically significant unless otherwise stated.

**Patient and public involvement**

Patients or the public will not be involved in the design, or conduct, or reporting, or dissemination plans of our research.

## Discussion

The FP-RESTORE will be the first study to provide prospective data on the effectiveness, safety and health economics evaluation of different endovascular modalities in the treatment of Tosaka III FP-ISR in a real-world setting. The endovascular treatments employed in FP-ISR include BA alone, DCB, cutting balloon, BMS, covered stent, mechanical debulking devices, laser atherectomy or a combination of the above.<sup>13-25</sup> However, the methods and results widely vary, which makes it difficult to compare the outcomes and make valid conclusions. FP-RESTORE is thus designed to evaluate and compare these endovascular procedures for Tosaka III FP-ISR. We hope our results will provide useful information and guidance about this issue and references for future controlled studies.

Clinically driven freedom from TLR is the primary outcome in our study. On the one hand, FP-RESTORE is designed to pay more attention to the clinical efficacy of various endovascular modalities; thus, clinically driven freedom from TLR could reflect the clinical effectiveness more intuitively. On the other hand, the inclusion criteria in real-world settings are not as strict as those of controlled studies; thus, a broader range of patients could be enrolled. Given that the patients are recruited throughout China, the imaging follow-up rate at different centres will vary widely, which may lead to missing information regarding primary patency. Thus, clinically driven freedom from TLR will serve as the primary outcome, whereas primary patency and other results will serve as secondary outcomes in this study.

## Dissemination



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1       The trial protocol complies with the Declaration of Helsinki. The study outcomes  
2 will be disseminated by publication in a peer-reviewed journal. The relevant  
3 confidential information will be transferred into a specific code to avoid potential  
4 leakage. In addition, the trial design has also been registered at ClinicalTrials.gov  
5 (Number: NCT04801004).

6       **Author Contributions:** The authors have been included in this manuscript based on  
7 the ICMJE recommendations. XL, MZ, YD, and ZS planned and designed the study.  
8 MY and ZW reviewed the structure of this manuscript. XL, MY, ZW ZF, LG, QL, XF  
9 and HS contributed to patient enrolments and collection of patient data. ZS critically  
10 reviewed and approved this manuscript. All authors have read and approved the final  
11 manuscript.

12       **Funding:** This work was supported by the National Natural Science Foundation of  
13 China (Grant number: 81870342 from ZS).

14       **Acknowledgements:** None

15       **Competing interests:** None

16       **Patient informed consent:** Obtained

17       **Ethics approval:** The study protocol was approved by the Institutional Review Board  
18 and Human Research Ethics Committee of Zhongshan Hospital, Fudan University  
19 (B2021-427).

20       **Provenance and peer review:** Not commissioned; externally peer reviewed.

21       **Data sharing:** No additional data are available.

22       **References**

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8 1. Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence
- 9
- 10 and risk factors for peripheral artery disease in 2000 and 2010: a systematic review
- 11
- 12 and analysis. *Lancet* 2013;382(9901):1329-40.
- 13
- 14
- 15 2. Ho KJ, Owens CD. Diagnosis, classification, and treatment of femoropopliteal
- 16
- 17 artery in-stent restenosis. *J Vasc Surg* 2017;65(2):545-57.
- 18
- 19
- 20 3. Shammass NW, Jones-Miller S, Lemke J. Meta-Analysis-Derived Benchmarks of
- 21
- 22 Patency and Target Lesion Revascularization of Percutaneous Balloon Angioplasty
- 23
- 24 from Prospective Clinical Trials of Symptomatic Femoropopliteal In-Stent
- 25
- 26 Restenosis. *J Vasc Interv Radiol* 2016;27(8):1195-203.
- 27
- 28
- 29
- 30 4. Tosaka A, Soga Y, Iida O, et al. Classification and clinical impact of restenosis
- 31
- 32 after femoropopliteal stenting. *J Am Coll Cardiol* 2012;59(1):16-23.
- 33
- 34
- 35 5. Armstrong EJ, Singh S, Singh GD, et al. Angiographic characteristics of
- 36
- 37 femoropopliteal in-stent restenosis: association with long-term outcomes after
- 38
- 39 endovascular intervention. *Catheter Cardiovasc Interv* 2013;82(7):1168-74.
- 40
- 41
- 42 6. Giannopoulos S, Kokkinidis DG, Jawaideh O, et al. Turbo-Power Laser Atherectomy
- 43
- 44 Combined with Drug-coated Balloon Angioplasty is Associated with Improved One-
- 45
- 46 Year Outcomes for the Treatment of Tosaka II and III Femoropopliteal In-stent
- 47
- 48 Restenosis. *Cardiovasc Revasc Med* 2020;21(6):771-78.
- 49
- 50
- 51 7. Zhang B, Niu G, Yan Z, et al. Drug-Coated Balloon for the Treatment of
- 52
- 53 Femoropopliteal Tosaka Class III In-stent Restenosis Lesions. *Front Surg*
- 54
- 55 2020;7:616414.
- 56
- 57
- 58
- 59
- 60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 8. Li X, Zhou M, Ding Y, et al. A systematic review and meta-analysis of the efficacy  
2 of debulking devices for in-stent restenosis of the femoropopliteal artery. *J Vasc Surg*  
3 2020;72(1):356-66 e5.

4 9. Beschorner U, Krankenberg H, Scheinert D, et al. Rotational and aspiration  
5 atherectomy for infrainguinal in-stent restenosis. *Vasa* 2013;42(2):127-33.

6 10. Shammass NW, Coiner D, Shammass GA, et al. Percutaneous lower-extremity  
7 arterial interventions with primary balloon angioplasty versus Silverhawk  
8 atherectomy and adjunctive balloon angioplasty: randomized trial. *J Vasc Interv*  
9 *Radiol* 2011;22(9):1223-8.

10 11. Sixt S, Carpio Cancino OG, Treszl A, et al. Drug-coated balloon angioplasty after  
11 directional atherectomy improves outcome in restenotic femoropopliteal arteries. *J*  
12 *Vasc Surg* 2013;58(3):682-6.

13 12. Trentmann J, Charalambous N, Djawanscher M, et al. Safety and efficacy of  
14 directional atherectomy for the treatment of in-stent restenosis of the femoropopliteal  
15 artery. *J Cardiovasc Surg (Torino)* 2010;51(4):551-60.

16 13. Dippel EJ, Makam P, Kovach R, et al. Randomized controlled study of excimer  
17 laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results  
18 from the EXCITE ISR trial (EXCimer Laser Randomized Controlled Study for  
19 Treatment of Femoropopliteal In-Stent Restenosis). *JACC Cardiovasc Interv*  
20 2015;8(1 Pt A):92-101.

21 14. Torsello G, Stavroulakis K, Brodmann M, et al. Three-Year Sustained Clinical  
22 Efficacy of Drug-Coated Balloon Angioplasty in a Real-World Femoropopliteal

- 1 Cohort. *J Endovasc Ther* 2020;27(5):693-705.
- 2 15. Beschorner U, Zeller T. Combination of mechanical atherectomy and drug-eluting  
3 balloons for femoropopliteal in-stent restenosis. *J Cardiovasc Surg (Torino)*  
4 2014;55(3):347-9.
- 5 16. Dick P, Sabeti S, Mlekusch W, et al. Conventional balloon angioplasty versus  
6 peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent  
7 restenosis: initial experience. *Radiology* 2008;248(1):297-302.
- 8 17. Gandini R, Del Giudice C, Merolla S, et al. Treatment of chronic SFA in-stent  
9 occlusion with combined laser atherectomy and drug-eluting balloon angioplasty in  
10 patients with critical limb ischemia: a single-center, prospective, randomized study. *J*  
11 *Endovasc Ther* 2013;20(6):805-14.
- 12 18. Kokkinidis DG, Behan S, Jawaid O, et al. Laser atherectomy and drug-coated  
13 balloons for the treatment of femoropopliteal in-stent restenosis: 2-Year outcomes.  
14 *Catheter Cardiovasc Interv* 2020;95(3):439-46.
- 15 19. Laird JR, Jr., Yeo KK, Rocha-Singh K, et al. Excimer laser with adjunctive  
16 balloon angioplasty and heparin-coated self-expanding stent grafts for the treatment  
17 of femoropopliteal artery in-stent restenosis: twelve-month results from the  
18 SALVAGE study. *Catheter Cardiovasc Interv* 2012;80(5):852-9.
- 19 20. Murata N, Takahara M, Soga Y, et al. Drug-Eluting Stent vs Percutaneous  
20 Transluminal Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis:  
21 Results From a Retrospective 1-Year Multicenter Study. *J Endovasc Ther*  
22 2016;23(4):642-7.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

21. Shamma NW, Shamma GA, Banerjee S, et al. JetStream Rotational and Aspiration Atherectomy in Treating In-Stent Restenosis of the Femoropopliteal Arteries: Results of the JETSTREAM-ISR Feasibility Study. *J Endovasc Ther* 2016;23(2):339-46.

22. Shamma NW, Shamma GA, Hafez A, et al. Safety and One-Year revascularization outcome of excimer laser ablation therapy in treating in-stent restenosis of femoropopliteal arteries: A retrospective review from a single center. *Cardiovasc Revasc Med* 2012;13(6):341-4.

23. Shamma NW, Shamma GA, Helou TJ, et al. Safety and 1-year revascularization outcome of SilverHawk atherectomy in treating in-stent restenosis of femoropopliteal arteries: a retrospective review from a single center. *Cardiovasc Revasc Med* 2012;13(4):224-7.

24. van den Berg JC, Pedrotti M, Canevascini R, et al. In-stent restenosis: mid-term results of debulking using excimer laser and drug-eluting balloons: sustained benefit? *J Invasive Cardiol* 2014;26(7):333-7.

25. Zeller T, Dake MD, Tepe G, et al. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents. *JACC Cardiovasc Interv* 2013;6(3):274-81.

# Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. BMJ. 2013;346:e7586

			Page Number
Reporting Item			
<b>Administrative information</b>			
Title	<a href="#">#1</a>	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	<a href="#">#2a</a>	Trial identifier and registry name. If not yet registered, name of intended registry	4
Trial registration: data set	<a href="#">#2b</a>	All items from the World Health Organization Trial Registration Data Set	5
Protocol version	<a href="#">#3</a>	Date and version identifier	5
Funding	<a href="#">#4</a>	Sources and types of financial, material, and other support	15
Roles and responsibilities: contributorship	<a href="#">#5a</a>	Names, affiliations, and roles of protocol contributors	1-2

1	Roles and	<a href="#">#5b</a>	Name and contact information for the trial sponsor	n/a
2	responsibilities:			
3	sponsor contact			
4	information			
5				
6				
7				
8	Roles and	<a href="#">#5c</a>	Role of study sponsor and funders, if any, in study design;	n/a
9	responsibilities:		collection, management, analysis, and interpretation of data;	
10	sponsor and funder		writing of the report; and the decision to submit the report for	
11			publication, including whether they will have ultimate authority	
12			over any of these activities	
13				
14				
15				
16	Roles and	<a href="#">#5d</a>	Composition, roles, and responsibilities of the coordinating centre,	15
17	responsibilities:		steering committee, endpoint adjudication committee, data	
18	committees		management team, and other individuals or groups overseeing the	
19			trial, if applicable (see Item 21a for data monitoring committee)	
20				
21				
22				
23	<b>Introduction</b>			
24				
25	Background and	<a href="#">#6a</a>	Description of research question and justification for undertaking	5-7
26	rationale		the trial, including summary of relevant studies (published and	
27			unpublished) examining benefits and harms for each intervention	
28				
29				
30				
31	Background and	<a href="#">#6b</a>	Explanation for choice of comparators	7
32	rationale: choice of			
33	comparators			
34				
35				
36	Objectives	<a href="#">#7</a>	Specific objectives or hypotheses	6
37				
38	Trial design	<a href="#">#8</a>	Description of trial design including type of trial (eg, parallel	7
39			group, crossover, factorial, single group), allocation ratio, and	
40			framework (eg, superiority, equivalence, non-inferiority,	
41			exploratory)	
42				
43				
44				
45	<b>Methods:</b>			
46	<b>Participants,</b>			
47	<b>interventions, and</b>			
48	<b>outcomes</b>			
49				
50				
51				
52	Study setting	<a href="#">#9</a>	Description of study settings (eg, community clinic, academic	7
53			hospital) and list of countries where data will be collected.	
54			Reference to where list of study sites can be obtained	
55				
56				
57	Eligibility criteria	<a href="#">#10</a>	Inclusion and exclusion criteria for participants. If applicable,	8-9
58			eligibility criteria for study centres and individuals who will	
59				
60				

		perform the interventions (eg, surgeons, psychotherapists)	
Interventions: description	<a href="#">#11a</a>	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	10
Interventions: modifications	<a href="#">#11b</a>	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	9-10
Interventions: adherence	<a href="#">#11c</a>	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	11
Interventions: concomitant care	<a href="#">#11d</a>	Relevant concomitant care and interventions that are permitted or prohibited during the trial	11-12
Outcomes	<a href="#">#12</a>	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	12
Participant timeline	<a href="#">#13</a>	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	12
Sample size	<a href="#">#14</a>	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	13
Recruitment	<a href="#">#15</a>	Strategies for achieving adequate participant enrolment to reach target sample size	11
<b>Methods: Assignment of interventions (for controlled trials)</b>			
Allocation: sequence generation	<a href="#">#16a</a>	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	n/a



1	Allocation concealment	<a href="#">#16b</a>	Mechanism of implementing the allocation sequence (eg, central	n/a
2	mechanism		telephone; sequentially numbered, opaque, sealed envelopes),	
3			describing any steps to conceal the sequence until interventions are	
4			assigned	
5				
6				
7				
8	Allocation:	<a href="#">#16c</a>	Who will generate the allocation sequence, who will enrol	n/a
9	implementation		participants, and who will assign participants to interventions	
10				
11	Blinding (masking)	<a href="#">#17a</a>	Who will be blinded after assignment to interventions (eg, trial	n/a
12			participants, care providers, outcome assessors, data analysts), and	
13			how	
14				
15				
16				
17	Blinding (masking):	<a href="#">#17b</a>	If blinded, circumstances under which unblinding is permissible,	n/a
18	emergency unblinding		and procedure for revealing a participant's allocated intervention	
19			during the trial	
20				
21				
22	<b>Methods: Data</b>			
23	<b>collection,</b>			
24	<b>management, and</b>			
25	<b>analysis</b>			
26				
27				
28				
29	Data collection plan	<a href="#">#18a</a>	Plans for assessment and collection of outcome, baseline, and other	11
30			trial data, including any related processes to promote data quality	
31			(eg, duplicate measurements, training of assessors) and a	
32			description of study instruments (eg, questionnaires, laboratory	
33			tests) along with their reliability and validity, if known. Reference	
34			to where data collection forms can be found, if not in the protocol	
35				
36				
37				
38				
39	Data collection plan:	<a href="#">#18b</a>	Plans to promote participant retention and complete follow-up,	11
40	retention		including list of any outcome data to be collected for participants	
41			who discontinue or deviate from intervention protocols	
42				
43				
44	Data management	<a href="#">#19</a>	Plans for data entry, coding, security, and storage, including any	11
45			related processes to promote data quality (eg, double data entry;	
46			range checks for data values). Reference to where details of data	
47			management procedures can be found, if not in the protocol	
48				
49				
50				
51	Statistics: outcomes	<a href="#">#20a</a>	Statistical methods for analysing primary and secondary outcomes.	13
52			Reference to where other details of the statistical analysis plan can	
53			be found, if not in the protocol	
54				
55				
56	Statistics: additional	<a href="#">#20b</a>	Methods for any additional analyses (eg, subgroup and adjusted	14
57	analyses		analyses)	
58				
59				
60				

Statistics: analysis population and missing data	<a href="#">#20c</a>	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	14
<b>Methods: Monitoring</b>			
Data monitoring: formal committee	<a href="#">#21a</a>	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	n/a
Data monitoring: interim analysis	<a href="#">#21b</a>	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	n/a
Harms	<a href="#">#22</a>	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	n/a
Auditing	<a href="#">#23</a>	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	n/a
<b>Ethics and dissemination</b>			
Research ethics approval	<a href="#">#24</a>	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	15
Protocol amendments	<a href="#">#25</a>	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	15
Consent or assent	<a href="#">#26a</a>	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	15
Consent or assent: ancillary studies	<a href="#">#26b</a>	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	15
Confidentiality	<a href="#">#27</a>	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	11

1	Declaration of interests	<a href="#">#28</a>	Financial and other competing interests for principal investigators for the overall trial and each study site	15
2				
3				
4				
5	Data access	<a href="#">#29</a>	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	11
6				
7				
8				
9				
10	Ancillary and post trial care	<a href="#">#30</a>	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a
11				
12				
13				
14	Dissemination policy: trial results	<a href="#">#31a</a>	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	15
15				
16				
17				
18				
19				
20				
21	Dissemination policy: authorship	<a href="#">#31b</a>	Authorship eligibility guidelines and any intended use of professional writers	15
22				
23				
24				
25	Dissemination policy: reproducible research	<a href="#">#31c</a>	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	15
26				
27				
28				
29	<b>Appendices</b>			
30				
31	Informed consent materials	<a href="#">#32</a>	Model consent form and other related documentation given to participants and authorised surrogates	n/a
32				
33				
34				
35	Biological specimens	<a href="#">#33</a>	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a
36				
37				
38				
39				

40 The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative Commons  
41 Attribution License CC-BY-NC. This checklist was completed on 10. December 2021 using  
42 <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59

# BMJ Open

## Design of the FP-RESTORE study: A protocol for prospective, observational study of real-world treatments with endovascular therapy in patients with femoropopliteal artery Tosaka III in-stent restenosis.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-060200.R3
Article Type:	Protocol
Date Submitted by the Author:	30-Oct-2022
Complete List of Authors:	<p>Li, Xu; Zhongshan Hospital Fudan University, Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine</p> <p>Zhou, Min; Zhongshan Hospital Fudan University, Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine</p> <p>Ding, Yong; Zhongshan Hospital Fudan University, Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine</p> <p>Wu, Ziheng; Zhejiang University School of Medicine First Affiliated Hospital, Department of Vascular Surgery</p> <p>Feng, Zibo; Liyuan Hospital of Tongji Medical College of Huazhong University of Science and Technology, Department of Vascular Surgery</p> <p>guo, Lianrui; Xuanwu Hospital Capital Medical University, Department of Vascular Surgery</p> <p>Li, Qiang; Qingdao Haici Hospital, Department of Vascular Surgery</p> <p>Fang, Xin; Affiliated Hangzhou First People's Hospital Zhejiang University School of Medicine, Department of Vascular Surgery</p> <p>Sang, Hongfei; Second Affiliated Hospital of Soochow University, Department of Vascular Surgery</p> <p>Ye, Meng; Shanghai Jiaotong University, Department of Vascular Surgery</p> <p>Shi, Zhenyu; Zhongshan Hospital Fudan University, Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine</p>
<b>Primary Subject Heading</b>:	Surgery
Secondary Subject Heading:	Surgery
Keywords:	Interventional radiology < RADIOLOGY & IMAGING, Vascular surgery < SURGERY, Clinical trials < THERAPEUTICS

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Design of the FP-RESTORE study: A protocol for prospective, observational study of real-world treatments with endovascular therapy in patients with femoropopliteal artery Tosaka III in-stent restenosis.**

**AUTHORS :**

**Xu Li**, Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine, Shanghai, China. **E-mail:** [lixu007qq@163.com](mailto:lixu007qq@163.com)

**Min Zhou**, Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine, Shanghai, China. E-mail: [med-zhou@foxmail.com](mailto:med-zhou@foxmail.com)

**Yong Ding**, Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, National Clinical Research Center for Interventional Medicine, Shanghai, China. E-mail: [Med.YoungDee@gmail.com](mailto:Med.YoungDee@gmail.com)

**Ziheng Wu**, Department of Vascular Surgery, the First Affiliated hospital of Medicine College of Zhejiang University, Hangzhou, China. E-mail: [wuziheng@zju.edu.cn](mailto:wuziheng@zju.edu.cn).

**Zibo Feng**, Department of Vascular Surgery, Liyuan Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan, China E-mail: [390306820@qq.com](mailto:390306820@qq.com)

**Lianrui Guo**, Department of Vascular Surgery, Xuanwu Hospital Capital Medical

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 University, Beijing, China E-mail: [lianruiguo@sina.com](mailto:lianruiguo@sina.com)

2 **Qiang Li**, Department of Vascular Surgery, Qingdao Haici hospital affiliated to

3 Qingdao University, Qingdao, China E-mail: [haicixueguan@163.com](mailto:haicixueguan@163.com)

4 **Xin Fang**, Department of Vascular Surgery, Hangzhou First People’s hospital of

5 Medical College of Zhejiang University, Hangzhou, China. E-mail:[hzfhfx@126.com](mailto:hzfhfx@126.com)

6 **Hongfei Sang**, Department of Vascular Surgery, the second Affiliated Hospital of

7 Medical College of Suzhou University, Suzhou, China. [sanghf@yahoo.com.cn](mailto:sanghf@yahoo.com.cn)

8 **Meng Ye\***, Department of Vascular Surgery, Renji Hospital, School of Medicine,

9 Shanghai Jiaotong University, Shanghai, China. Email:

10 [doctor\\_yemeng2018@163.com](mailto:doctor_yemeng2018@163.com)

11 **Zhenyu Shi\***, Department of Vascular Surgery, Zhongshan Hospital, Institute of

12 Vascular Surgery, Fudan University, National Clinical Research Center for

13 Interventional Medicine, Shanghai, China. E-mail: [shizhenyumax@163.com](mailto:shizhenyumax@163.com)

14

15 Xu Li\* and Min Zhou\* contribute to this work equally.

16 **Word count, total:** 2588

17 **Word count, abstract:**243

18 **CORRESPONDING AUTHOR:**

19 Zhenyu Shi, MD, PhD

20 Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery,

21 Fudan University, National Clinical Research Center for Interventional Medicine,

22 Shanghai, China.

1 180 Fenglin Road, 200032, Shanghai, China

2 &

3 Meng Ye, MD, PhD

4 Department of Vascular Surgery, Renji Hospital, School of Medicine, Shanghai

5 Jiaotong University

6 Pujian Road 160, Shanghai 200127, China.

7 Email: doctor\_yemeng2018@163.com

8 Tel.: 8621-6404-1990 ext. 2359

9 Fax: 8621-6443-2410

10 E-mail address: shizhenyumax@163.com

11

12

13

14

15

16

17

18

19

20

21

22



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Abstract**

**Introduction:** Femoropopliteal artery in-stent restenosis (FP-ISR) represents one of the main obstacles for stent implantation in PAD patients, especially Tosaka III FP-ISR, which is also referred to as in-stent occlusion. Diverse endovascular treatments of Tosaka III FP-ISR are available, and the results are unequivocal. However, real-world data are limited. This study aims to evaluate the efficacy, safety and health economics evaluation of various endovascular procedures in the treatment of Tosaka III FP-ISR.

**Method and analysis**

This study is a prospective, multicentre, real-world, observational clinical study. Patients diagnosed with Tosaka III FP-ISR and treated with endovascular procedures in 9 centres from 1 April 2021 to 31 December 2022 will be recruited. The relevant clinical information, ankle-brachial index and CT angiography will be collected. All the participants will undergo follow-up at 1, 6, 12, 18 and 24 months after the operation. The primary outcome is freedom from clinically driven target lesion revascularization (CD-TLR) at 24 months. Safety and health economics issues will also be reported.

**Ethics and dissemination**

The FP-RESTORE clinical trial has been registered at ClinicalTrials.gov (<http://clinicaltrials.gov/>). This study was also approved by the Institutional Review Board and Human Research Ethics Committee of Zhongshan Hospital, Fudan

University (approval number: B2021-427). Moreover, written informed consent will be obtained at the time of recruitment. The study outcomes will be disseminated by publication in a peer-reviewed journal to provide information for further clinical practice.

**Trial registration number:** NCT04801004.

**Protocol version and date:** V.1.2, 1 August 2022.

### **Strengths and limitations of this study**

1. This study is a prospective, multicentre, real-world, observational clinical study.
2. This study focuses on the efficacy, safety and health economics evaluation of various endovascular operations in the treatment of Tosaka III FP-ISR.
3. This is an observational study, and no interference with endovascular treatments will occur.
4. The revascularization of Tosaka III FP-ISR is associated with poor outcomes.

### **Introduction:**

The femoropopliteal artery is one of most commonly treated peripheral artery diseases (PAD).<sup>1</sup> The treatment modalities mainly include conservative treatment, endovascular procedures and surgical operations, with endovascular treatment being more widely applied. However, femoropopliteal artery in-stent restenosis (FP-ISR) has become one of the main blocks for stent implantation in PAD patients with high

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 morbidity, especially Tosaka III in-stent restenosis, which is also referred to as in-  
2 stent obstruction.<sup>2 3</sup> Tosaka et al. reported that the freedom from recurrent ISR at 12  
3 months was 22.7% for Tosaka III lesions compared with 72.5% and 65.6% for Tosaka  
4 I and II lesions, respectively.<sup>4</sup> Armstrong et al. reported that the freedom from  
5 recurrent restenosis at 24 months was 28% for Tosaka III lesions compared with 61%  
6 and 34% for TOSAKA I and II lesions, respectively.<sup>5</sup> This finding indicated that in-  
7 stent occlusion correlated with a worse prognosis than in-stent restenosis.

8       Giannopoulos et al. reported freedom from TLR of 88.9% in the laser debulking  
9 devices (LD) + drug coated balloons (DCB) group compared with 54.2% in the LD +  
10 balloon angioplasty (BA) group in a 12-month estimate for the treatment of Tosaka III  
11 FP-ISR.<sup>6</sup> Zhang et al. reported the results of DCB in the treatment of Tosaka III FP-  
12 ISR with primary patency and freedom from TLR estimates of 79.2% and 91.5%,  
13 respectively, at the 14-month follow-up.<sup>7</sup> Debulking devices (laser debulking or  
14 mechanical debulking devices) have also been widely used in the treatment of FP-  
15 ISR. Our previous meta-analysis demonstrated that patients with long and occlusive  
16 ISR lesions benefit more from debulking devices.<sup>8</sup> Previous studies have also reported  
17 roles for mechanical atherothrombectomy in the treatment of Tosaka III in-stent  
18 restenosis with freedom from TLR at 12 months ranging from 43.8% to 84.7%.<sup>9-12</sup>  
19 Given that the outcomes for endovascularly treated Tosaka III FP-ISR varied, there is  
20 a need for data from a real-world setting to evaluate the safety, efficacy and economic  
21 cost of different endovascular modalities in the treatment of Tosaka III FP-ISR. In a  
22 real-world setting, the trial could recruit patients with in-stent occlusion rather than

1 mild in-stent restenosis lesions.

2 Although there have been clinical reports about the preliminary and midterm  
3 stage results of different endovascular treatments in the treatment of Tosaka III FP-  
4 ISR patients, these results were still insufficient to reflect real-world clinical practice.  
5 Thus, we initiated a clinical trial named the FP-RESTORE study to examine the  
6 safety, effectiveness and economic cost of different endovascular therapies in the  
7 treatment of Tosaka III FP-ISR patients in a real-world setting across China.

## 8 **METHODS**

### 9 **Study design**

10 FP-RESTORE is a prospective, multicentre, real-world, observational clinical study  
11 that aims to evaluate the safety, efficacy and economic cost of different endovascular  
12 therapies in Tosaka III (totally occluded) in-stent restenosis. It is estimated that 300  
13 subjects diagnosed with femoropopliteal artery Tosaka III in-stent restenosis and  
14 receiving endovascular treatments will be enrolled in nine centres from April 2021 to  
15 December 2022 nationwide in China. No restrictions on the endovascular techniques  
16 used will be employed to make it easier to compare the effects of different  
17 endovascular treatments in Tosaka III in-stent restenosis.

18 The main purpose is to observe the freedom from clinically driven target lesion  
19 revascularization (CD-TLR), primary patency, the improvement in quality-of-life  
20 score, and health economics evaluation.

21 The study was designed and initiated by the Department of Vascular Surgery,  
22 Zhongshan Hospital, Fudan University. No patient or public involvement is required.

**Participants**

To minimize bias in the selection of patients, investigators at participating sites are encouraged to recruit all eligible Tosaka III in-stent restenosis patients receiving endovascular treatments. The patients will be screened for enrolment from April 2021 to December 2022 in nine designated centres across China. A total of 300 patients who received stent implantation to treat PAD and developed Tosaka III FP-ISR will be recruited. Recruitment is non-competitive and will not affect clinical practice.

**CRITERIA**

**Inclusion criteria**

1. Tosaka III In-stent restenosis after stent implantation in PAD patients (Including acute and subacute thrombotic lesions).
2. Rutherford grade 2-5.
3. Stents should be located in the femoropopliteal artery.
4. The stenosis of iliac artery on the affected side is less than 30% or the residual stenosis after treatment is less than 30%.
5. Informed consent has been signed

**Exclusion criteria**

1. Tosaka I or II in-stent restenosis.
2. Stents are located in iliac artery or artery below the knee, or the preoperative CTA showed type 3 or 4 stent fracture.
3. Rutherford Grade 6.
4. Thromboangiitis obliterans (TAO)-based, arteritis-based or connective tissue

1 disorder-based FP-ISR.

2 5. Intraoperative conversion to hybrid or open surgery.

3 6. Patients refusing to sign informed consent forms.

4 7. Life expectancy of patients is less than 12 months.

5 8. The pregnant or nursing patients.

6 9. The patients with severe ischemia of lower extremity who would receive major  
7 amputation in plan.

8 10. Patients in whom antiplatelet or anticoagulant therapy is contraindicated.

9 11. Myocardial infarction or stroke within 3 months prior to enrolment.

10 12. Patient with known allergy to contrast agents or medications used to perform  
11 endovascular intervention.

12 13. Patients participating in another research study involving an investigational agent  
13 (pharmaceutical, biologic, or medical device) that has not reached the primary  
14 endpoint.

15 14. Patients who refuse to cooperate with long-term follow-up or who have difficulty  
16 communicating.

17

## 18 **Criteria for discontinuing**

19 Subjects could discontinue participation in this trial at any time for any reason without  
20 any consequences. In addition, the investigators could decide whether the patient is  
21 excluded from the study depending on the following conditions.

22 1. The patients are lost to follow-up.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1     2. The patients voluntarily withdraw their informed consent.
- 2     3. In case of serious violation of the study protocol by investigators or subjects.
- 3     4. Patient is simultaneously participating in another investigational drug or device
- 4     study.
- 5     5. Patient has any planned surgical or interventional procedure within 30 days after the
- 6     study procedure.
- 7     Once the subject discontinued participation in the trial, his or her relevant primary
- 8     outcomes and secondary outcomes would be eliminated.

9

10     **Endovascular procedure**

11         All enrolled patients will be treated with endovascular therapies. In general,

12     endovascular approaches are established from the contralateral common femoral

13     artery or the ipsilateral common femoral artery or a brachial approach. Retrograde

14     puncture access via the popliteal artery will be chosen once intervention with the

15     antegrade approach is unsuccessful. Angiography will be performed to assess the

16     lesion severity, length and location. Then, angiography of the target artery will be

17     performed, and the guide wire will be passed through the in-stent occlusion lesion.

18     Then, multiple types of endovascular treatments, including BA, DCB, drug eluting

19     stent (DES) implantation, bare metal stent (BMS) implantation, intravascular

20     lithotripsy, directional atherectomy, laser debulking, stent-graft implantation or a

21     combination of the above, will be applied according to the characteristics of the lesion

22     and physician preferences. Generally, BA and DCB will be used as the basis for

1 endovascular treatment of FR-ISR. Thrombectomy devices will be applied in acute or  
2 subacute thrombosis lesions, and both laser debulking devices and atherectomy  
3 debulking devices are preferred in chronic long lesions. The devices used  
4 intraoperatively will be based on the operator's preferences. Final angiography will be  
5 performed to assess the efficacy of endovascular treatment. Residual stenosis of less  
6 than 30% will be defined as technical success.

## 8 **Recruitment**

9 All suitable patients will receive a routine examination during admission. Patients  
10 will receive intraoperative angiography of lower extremity artery, and data on the  
11 lesion length, stenosis degree, extent of lesion, collateral circulation will be assessed.  
12 Moreover, eligible patients will be enrolled after signing the informed consent form.

## 13 **Data collection**

14 A standard case report form (CRF) has been established at the beginning of this study.  
15 This CRF will collect the patients' quality of life (QoL), systemic disease history,  
16 perioperative risk factor assessment, clinical symptom classification, lesion location  
17 and Trans-Atlantic Inter-Society Consensus II (TASC) classification, endovascular  
18 procedure details, treatment outcomes and complications as well as follow-up  
19 information. Two investigators will perform the data input independently, and data  
20 input verification will be conducted to reduce the chance of error. The original CRF  
21 will be archived by the sponsor, and a copy of the CRF will be kept at the centre and  
22 transferred into electronic records in a correlated data management system. This



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 system covers preoperative assessment, intraoperative details and follow-up  
2 information.

3

4 **Surveillance and follow-up**

5 Follow-up will be coordinated by each participating centre independently. The  
6 follow-up information will be obtained via telephone interviews and outpatient  
7 clinical visits. To improve the shortcoming of the detail of reintervention cannot be  
8 acquired in telephone follow-up, we would encourage the participants to provide the  
9 medical records of reintervention detail and conduct the outpatient visit immediately  
10 if he received reintervention during follow-up period. The telephone interview follow-  
11 up information includes ambulation improvements, current medication, smoking  
12 status, wound healing (if necessary), rehospitalization and quality of life. Outpatient  
13 clinical visit follow-up information includes ABI, Rutherford classification, vascular  
14 ultrasound, the need for reintervention and the presence of new-onset lesions.

15 These relevant details will also be recorded in the CRF and transferred into  
16 electronic records in the lower extremity artery data management system. All centres  
17 participating in this study will have access to the data. The participant’s personal  
18 information will be encrypted to prevent leakage. All the participants will undergo  
19 follow-up at 1, 6, 12, 18 and 24 months after the operation.

20 **Outcome measures**

21 The primary outcome of the study is freedom from clinically driven TLR at 24  
22 months. CD-TLR is defined as any reintervention within the target lesion(s) because

of recurrent symptoms. Freedom from CD-TLR is defined as the rate of the number of patients who did not receive reintervention versus the number of patients during the follow-up period.<sup>13 14</sup> The secondary outcomes include 1) primary patency, which was defined as the percentage of stent patency examined by DUS or CTA examination during follow-up; 2) technical success rate; 3) incidence of major adverse events; 4) freedom from CD-TLR at 1, 6, 12 and 18 months; 5) assessment using The Vascular Quality of Life Questionnaire (VascuQoL), which contains five domains to evaluate health-related quality of life (HRQL), including pain (4 items), symptoms (4 items), activities (8 items), social (2 items), and emotional (7 items); and 6) health economics evaluation, which is defined as all the costs related to the target vessel revascularization in the inpatient ward. Moreover, the health economics evaluation of technique failed participants will also be included.

### **Adverse events**

The adverse events will be categorized into minor and major adverse events, and the frequency of minor and major adverse events during the treatment period and follow-up period will both be recorded. The minor adverse events included arterial puncture complications, distal embolism without clinical manifestations, postoperative thrombosis without critical limb ischemia, and reversible contrast induced nephropathy. In addition, major adverse events include major amputation related to endovascular treatment, cardio- and cerebrovascular events, arterial puncture complications requiring intervention, progressive haemoglobin disease, acute renal failure and death. Once adverse events are identified, the corresponding

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 centres will actively manage and report the adverse events. The adverse events and  
2 the process of treatment will be documented and reported to the corresponding ethics  
3 committee. Once death events occur, the corresponding centres and the participating  
4 investigator should immediately provide all necessary information to the ethics  
5 committee.

6  
7 **Sample size and statistical analysis**

8 Taking into account a 10% lost to follow-up rate and a target enrolment of 300  
9 patients, 270 patients will be included in the effectiveness analysis.

10 Statistical analysis will be performed using Stata SE 15.1 software (Stata Corp,  
11 College Station, TX, USA). Continuous data will be presented as the mean  $\pm$  standard  
12 deviation, and categorical data will be presented as numbers (n) and percentages (%).

13 Normal distribution and homogeneous tests of variance will be performed in  
14 advance. For the data groups that have a normal distribution and homogeneous  
15 variances, comparisons between two groups will be made using unpaired Student's t  
16 tests and one-way ANOVA followed by Bonferroni tests for multiple group  
17 comparisons. For the data groups that do not have a normal distribution or  
18 homogeneous variances, nonparametric tests will be used. Univariate and multivariate  
19 analyses will be performed by logistic analysis. Generally, a two-sided *P* value < 0.05  
20 will be considered statistically significant unless otherwise stated.

21  
22 **Patient and public involvement**

Patients or the public will not be involved in the design, or conduct, or reporting, or dissemination plans of our research.

## Discussion

The FP-RESTORE will be the first study to provide prospective data on the effectiveness, safety and health economics evaluation of different endovascular modalities in the treatment of Tosaka III FP-ISR in a real-world setting. The endovascular treatments employed in FP-ISR include BA alone, DCB, cutting balloon, BMS, covered stent, mechanical debulking devices, laser atherectomy or a combination of the above.<sup>13-25</sup> However, the methods and results widely vary, which makes it difficult to compare the outcomes and make valid conclusions. FP-RESTORE is thus designed to evaluate and compare these endovascular procedures for Tosaka III FP-ISR. We hope our results will provide useful information and guidance about this issue and references for future controlled studies.

Clinically driven freedom from TLR is the primary outcome in our study. On the one hand, FP-RESTORE is designed to pay more attention to the clinical efficacy of various endovascular modalities; thus, clinically driven freedom from TLR could reflect the clinical effectiveness more intuitively. On the other hand, the inclusion criteria in real-world settings are not as strict as those of controlled studies; thus, a broader range of patients could be enrolled. Given that the patients are recruited throughout China, the imaging follow-up rate at different centres will vary widely, which may lead to missing information regarding primary patency. Thus, clinically

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 driven freedom from TLR will serve as the primary outcome, whereas primary  
2 patency and other results will serve as secondary outcomes in this study.

3 The patient's enrolment started at April 1, 2021 actually. The inclusion criteria "  
4 The length of occluded lesion is  $\geq$  5cm." and the exclusion criteria " or stent  
5 occlusion lesion less than 5cm in length" has been deleted in August 13, 2022 to keep  
6 consistent with Tosaka classifications. Since this study was a real-world setting  
7 observational study, we discussed with statistician in our group and concluded the  
8 modification of inclusion and exclusion was acceptable in post-hoc adaptation period.

9 **Dissemination**

10 The trial protocol complies with the Declaration of Helsinki. The study outcomes  
11 will be disseminated by publication in a peer-reviewed journal. The relevant  
12 confidential information will be transferred into a specific code to avoid potential  
13 leakage. In addition, the trial design has also been registered at ClinicalTrials.gov  
14 (Number: NCT04801004).

15 **Author Contributions:** The authors have been included in this manuscript based on  
16 the ICMJE recommendations. XL, MZ, YD, and ZS planned and designed the study.  
17 MY and ZW reviewed the structure of this manuscript. XL, MY, ZW ZF, LG, QL, XF  
18 and HS contributed to patient enrolments and collection of patient data. ZS critically  
19 reviewed and approved this manuscript. All authors have read and approved the final  
20 manuscript.

21 **Funding:** This work was supported by the National Natural Science Foundation of  
22 China (Grant number: 81870342 from ZS).

**Acknowledgements:** None

**Competing interests:** None

**Patient informed consent:** Obtained

**Ethics approval:** The study protocol was approved by the Institutional Review Board and Human Research Ethics Committee of Zhongshan Hospital, Fudan University (B2021-427).

**Provenance and peer review:** Not commissioned; externally peer reviewed.

**Data sharing:** No additional data are available.

## References

1. Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. *Lancet* 2013;382(9901):1329-40.
2. Ho KJ, Owens CD. Diagnosis, classification, and treatment of femoropopliteal artery in-stent restenosis. *J Vasc Surg* 2017;65(2):545-57.
3. Shamma NW, Jones-Miller S, Lemke J. Meta-Analysis-Derived Benchmarks of Patency and Target Lesion Revascularization of Percutaneous Balloon Angioplasty from Prospective Clinical Trials of Symptomatic Femoropopliteal In-Stent Restenosis. *J Vasc Interv Radiol* 2016;27(8):1195-203.
4. Tosaka A, Soga Y, Iida O, et al. Classification and clinical impact of restenosis after femoropopliteal stenting. *J Am Coll Cardiol* 2012;59(1):16-23.
5. Armstrong EJ, Singh S, Singh GD, et al. Angiographic characteristics of

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 femoropopliteal in-stent restenosis: association with long-term outcomes after  
2 endovascular intervention. *Catheter Cardiovasc Interv* 2013;82(7):1168-74.

3 6. Giannopoulos S, Kokkinidis DG, Jawaaid O, et al. Turbo-Power Laser Atherectomy  
4 Combined with Drug-coated Balloon Angioplasty is Associated with Improved One-  
5 Year Outcomes for the Treatment of Tosaka II and III Femoropopliteal In-stent  
6 Restenosis. *Cardiovasc Revasc Med* 2020;21(6):771-78.

7 7. Zhang B, Niu G, Yan Z, et al. Drug-Coated Balloon for the Treatment of  
8 Femoropopliteal Tosaka Class III In-stent Restenosis Lesions. *Front Surg*  
9 2020;7:616414.

10 8. Li X, Zhou M, Ding Y, et al. A systematic review and meta-analysis of the efficacy  
11 of debulking devices for in-stent restenosis of the femoropopliteal artery. *J Vasc Surg*  
12 2020;72(1):356-66 e5.

13 9. Beschorner U, Krankenberg H, Scheinert D, et al. Rotational and aspiration  
14 atherectomy for infrainguinal in-stent restenosis. *Vasa* 2013;42(2):127-33.

15 10. Shammass NW, Coiner D, Shammass GA, et al. Percutaneous lower-extremity  
16 arterial interventions with primary balloon angioplasty versus Silverhawk  
17 atherectomy and adjunctive balloon angioplasty: randomized trial. *J Vasc Interv*  
18 *Radiol* 2011;22(9):1223-8.

19 11. Sixt S, Carpio Cancino OG, Treszl A, et al. Drug-coated balloon angioplasty after  
20 directional atherectomy improves outcome in restenotic femoropopliteal arteries. *J*  
21 *Vasc Surg* 2013;58(3):682-6.

22 12. Trentmann J, Charalambous N, Djawanscher M, et al. Safety and efficacy of

- directional atherectomy for the treatment of in-stent restenosis of the femoropopliteal artery. *J Cardiovasc Surg (Torino)* 2010;51(4):551-60.
13. Dippel EJ, Makam P, Kovach R, et al. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCimer Laser Randomized Controlled Study for Treatment of Femoropopliteal In-Stent Restenosis). *JACC Cardiovasc Interv* 2015;8(1 Pt A):92-101.
14. Torsello G, Stavroulakis K, Brodmann M, et al. Three-Year Sustained Clinical Efficacy of Drug-Coated Balloon Angioplasty in a Real-World Femoropopliteal Cohort. *J Endovasc Ther* 2020;27(5):693-705.
15. Beschorner U, Zeller T. Combination of mechanical atherectomy and drug-eluting balloons for femoropopliteal in-stent restenosis. *J Cardiovasc Surg (Torino)* 2014;55(3):347-9.
16. Dick P, Sabeti S, Mlekusch W, et al. Conventional balloon angioplasty versus peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent restenosis: initial experience. *Radiology* 2008;248(1):297-302.
17. Gandini R, Del Giudice C, Merolla S, et al. Treatment of chronic SFA in-stent occlusion with combined laser atherectomy and drug-eluting balloon angioplasty in patients with critical limb ischemia: a single-center, prospective, randomized study. *J Endovasc Ther* 2013;20(6):805-14.
18. Kokkinidis DG, Behan S, Jawaidd O, et al. Laser atherectomy and drug-coated balloons for the treatment of femoropopliteal in-stent restenosis: 2-Year outcomes.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1     *Catheter Cardiovasc Interv* 2020;95(3):439-46.

2     19. Laird JR, Jr., Yeo KK, Rocha-Singh K, et al. Excimer laser with adjunctive

3     balloon angioplasty and heparin-coated self-expanding stent grafts for the treatment

4     of femoropopliteal artery in-stent restenosis: twelve-month results from the

5     SALVAGE study. *Catheter Cardiovasc Interv* 2012;80(5):852-9.

6     20. Murata N, Takahara M, Soga Y, et al. Drug-Eluting Stent vs Percutaneous

7     Transluminal Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis:

8     Results From a Retrospective 1-Year Multicenter Study. *J Endovasc Ther*

9     2016;23(4):642-7.

10    21. Shammass NW, Shammass GA, Banerjee S, et al. JetStream Rotational and

11    Aspiration Atherectomy in Treating In-Stent Restenosis of the Femoropopliteal

12    Arteries: Results of the JETSTREAM-ISR Feasibility Study. *J Endovasc Ther*

13    2016;23(2):339-46.

14    22. Shammass NW, Shammass GA, Hafez A, et al. Safety and One-Year

15    revascularization outcome of excimer laser ablation therapy in treating in-stent

16    restenosis of femoropopliteal arteries: A retrospective review from a single center.

17    *Cardiovasc Revasc Med* 2012;13(6):341-4.

18    23. Shammass NW, Shammass GA, Helou TJ, et al. Safety and 1-year revascularization

19    outcome of SilverHawk atherectomy in treating in-stent restenosis of femoropopliteal

20    arteries: a retrospective review from a single center. *Cardiovasc Revasc Med*

21    2012;13(4):224-7.

22    24. van den Berg JC, Pedrotti M, Canevascini R, et al. In-stent restenosis: mid-term

- 1 results of debulking using excimer laser and drug-eluting balloons: sustained benefit?
- 2 *J Invasive Cardiol* 2014;26(7):333-7.
- 3 25. Zeller T, Dake MD, Tepe G, et al. Treatment of femoropopliteal in-stent
- 4 restenosis with paclitaxel-eluting stents. *JACC Cardiovasc Interv* 2013;6(3):274-81.
- 5

For peer review only

# Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRITreporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. BMJ. 2013;346:e7586

Reporting Item			Page Number
<b>Administrative information</b>			
Title	<a href="#">#1</a>	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	<a href="#">#2a</a>	Trial identifier and registry name. If not yet registered, name of intended registry	4
Trial registration: data set	<a href="#">#2b</a>	All items from the World Health Organization Trial Registration Data Set	5
Protocol version	<a href="#">#3</a>	Date and version identifier	5
Funding	<a href="#">#4</a>	Sources and types of financial, material, and other support	15
Roles and responsibilities: contributorship	<a href="#">#5a</a>	Names, affiliations, and roles of protocol contributors	1-2

1	Roles and	<a href="#">#5b</a>	Name and contact information for the trial sponsor	n/a
2	responsibilities:			
3	sponsor contact			
4	information			
5				
6				
7				
8	Roles and	<a href="#">#5c</a>	Role of study sponsor and funders, if any, in study design;	n/a
9	responsibilities:		collection, management, analysis, and interpretation of data;	
10	sponsor and funder		writing of the report; and the decision to submit the report for	
11			publication, including whether they will have ultimate authority	
12			over any of these activities	
13				
14				
15				
16	Roles and	<a href="#">#5d</a>	Composition, roles, and responsibilities of the coordinating centre,	15
17	responsibilities:		steering committee, endpoint adjudication committee, data	
18	committees		management team, and other individuals or groups overseeing the	
19			trial, if applicable (see Item 21a for data monitoring committee)	
20				
21				
22				
23	<b>Introduction</b>			
24				
25	Background and	<a href="#">#6a</a>	Description of research question and justification for undertaking	5-7
26	rationale		the trial, including summary of relevant studies (published and	
27			unpublished) examining benefits and harms for each intervention	
28				
29				
30				
31	Background and	<a href="#">#6b</a>	Explanation for choice of comparators	7
32	rationale: choice of			
33	comparators			
34				
35				
36	Objectives	<a href="#">#7</a>	Specific objectives or hypotheses	6
37				
38	Trial design	<a href="#">#8</a>	Description of trial design including type of trial (eg, parallel	7
39			group, crossover, factorial, single group), allocation ratio, and	
40			framework (eg, superiority, equivalence, non-inferiority,	
41			exploratory)	
42				
43				
44				
45	<b>Methods:</b>			
46	<b>Participants,</b>			
47	<b>interventions, and</b>			
48	<b>outcomes</b>			
49				
50				
51				
52	Study setting	<a href="#">#9</a>	Description of study settings (eg, community clinic, academic	7
53			hospital) and list of countries where data will be collected.	
54			Reference to where list of study sites can be obtained	
55				
56				
57	Eligibility criteria	<a href="#">#10</a>	Inclusion and exclusion criteria for participants. If applicable,	8-9
58			eligibility criteria for study centres and individuals who will	
59				
60				

		perform the interventions (eg, surgeons, psychotherapists)	
Interventions: description	<a href="#">#11a</a>	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	10
Interventions: modifications	<a href="#">#11b</a>	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	9-10
Interventions: adherence	<a href="#">#11c</a>	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	11
Interventions: concomitant care	<a href="#">#11d</a>	Relevant concomitant care and interventions that are permitted or prohibited during the trial	11-12
Outcomes	<a href="#">#12</a>	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	12
Participant timeline	<a href="#">#13</a>	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	12
Sample size	<a href="#">#14</a>	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	13
Recruitment	<a href="#">#15</a>	Strategies for achieving adequate participant enrolment to reach target sample size	11
<b>Methods: Assignment of interventions (for controlled trials)</b>			
Allocation: sequence generation	<a href="#">#16a</a>	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	n/a

Allocation concealment mechanism	<a href="#">#16b</a>	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	n/a
Allocation: implementation	<a href="#">#16c</a>	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	n/a
Blinding (masking)	<a href="#">#17a</a>	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	n/a
Blinding (masking): emergency unblinding	<a href="#">#17b</a>	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	n/a
<b>Methods: Data collection, management, and analysis</b>			
Data collection plan	<a href="#">#18a</a>	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	11
Data collection plan: retention	<a href="#">#18b</a>	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	11
Data management	<a href="#">#19</a>	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	11
Statistics: outcomes	<a href="#">#20a</a>	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	13
Statistics: additional analyses	<a href="#">#20b</a>	Methods for any additional analyses (eg, subgroup and adjusted analyses)	14

1	Statistics: analysis	<a href="#">#20c</a>	Definition of analysis population relating to protocol non-	14
2	population and missing		adherence (eg, as randomised analysis), and any statistical methods	
3	data		to handle missing data (eg, multiple imputation)	
4				
5				
6	<b>Methods: Monitoring</b>			
7				
8				
9	Data monitoring:	<a href="#">#21a</a>	Composition of data monitoring committee (DMC); summary of its	n/a
10	formal committee		role and reporting structure; statement of whether it is independent	
11			from the sponsor and competing interests; and reference to where	
12			further details about its charter can be found, if not in the protocol.	
13			Alternatively, an explanation of why a DMC is not needed	
14				
15				
16				
17	Data monitoring:	<a href="#">#21b</a>	Description of any interim analyses and stopping guidelines,	n/a
18	interim analysis		including who will have access to these interim results and make	
19			the final decision to terminate the trial	
20				
21				
22	Harms	<a href="#">#22</a>	Plans for collecting, assessing, reporting, and managing solicited	n/a
23			and spontaneously reported adverse events and other unintended	
24			effects of trial interventions or trial conduct	
25				
26				
27				
28	Auditing	<a href="#">#23</a>	Frequency and procedures for auditing trial conduct, if any, and	n/a
29			whether the process will be independent from investigators and the	
30			sponsor	
31				
32				
33	<b>Ethics and</b>			
34	<b>dissemination</b>			
35				
36				
37	Research ethics	<a href="#">#24</a>	Plans for seeking research ethics committee / institutional review	15
38	approval		board (REC / IRB) approval	
39				
40				
41	Protocol amendments	<a href="#">#25</a>	Plans for communicating important protocol modifications (eg,	15
42			changes to eligibility criteria, outcomes, analyses) to relevant	
43			parties (eg, investigators, REC / IRBs, trial participants, trial	
44			registries, journals, regulators)	
45				
46				
47	Consent or assent	<a href="#">#26a</a>	Who will obtain informed consent or assent from potential trial	15
48			participants or authorised surrogates, and how (see Item 32)	
49				
50				
51	Consent or assent:	<a href="#">#26b</a>	Additional consent provisions for collection and use of participant	15
52	ancillary studies		data and biological specimens in ancillary studies, if applicable	
53				
54				
55	Confidentiality	<a href="#">#27</a>	How personal information about potential and enrolled participants	11
56			will be collected, shared, and maintained in order to protect	
57			confidentiality before, during, and after the trial	
58				
59				
60				



1	Declaration of interests	<a href="#">#28</a>	Financial and other competing interests for principal investigators for the overall trial and each study site	15
2				
3				
4				
5	Data access	<a href="#">#29</a>	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	11
6				
7				
8				
9				
10	Ancillary and post trial care	<a href="#">#30</a>	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a
11				
12				
13				
14	Dissemination policy: trial results	<a href="#">#31a</a>	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	15
15				
16				
17				
18				
19				
20				
21	Dissemination policy: authorship	<a href="#">#31b</a>	Authorship eligibility guidelines and any intended use of professional writers	15
22				
23				
24	Dissemination policy: reproducible research	<a href="#">#31c</a>	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	15
25				
26				
27				
28	<b>Appendices</b>			
29				
30				
31	Informed consent materials	<a href="#">#32</a>	Model consent form and other related documentation given to participants and authorised surrogates	n/a
32				
33				
34	Biological specimens	<a href="#">#33</a>	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a
35				
36				
37				
38				
39				

The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative Commons Attribution License CC-BY-NC. This checklist was completed on 10. December 2021 using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)